View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Mar. 31, 2019	Apr. 30, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Trading Symbol	HAIN
Entity Registrant Name	HAIN CELESTIAL GROUP INC.
Entity Central Index Key	0000910406
Current Fiscal Year End Date	--06-30
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		104,149,062

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
ASSETS
Cash and cash equivalents	$ 27,562	$ 106,557
Restricted cash	34,452	0
Accounts receivable, less allowance for doubtful accounts of $405 and $1,828, respectively	256,799	252,708
Inventories	395,246	391,525
Prepaid expenses and other current assets	54,786	59,946
Current assets of discontinued operations	136,181	240,851
Total current assets	905,026	1,051,587
Property, plant and equipment, net	331,070	310,172
Goodwill	1,016,863	1,024,136
Trademarks and other intangible assets, net	475,582	510,387
Investments and joint ventures	19,228	20,725
Other assets	30,502	29,667
Total assets	2,778,271	2,946,674
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	205,014	229,993
Accrued expenses and other current liabilities	176,400	116,001
Current portion of long-term debt	22,522	26,605
Current liabilities of discontinued operations	15,195	49,846
Total current liabilities	419,131	422,445
Long-term debt, less current portion	729,201	687,501
Deferred income taxes	63,619	86,909
Other noncurrent liabilities	16,528	12,770
Total liabilities	1,228,479	1,209,625
Commitments and contingencies (Note 16)
Stockholders’ equity:
Preferred stock - $.01 par value, authorized 5,000 shares; issued and outstanding: none	0	0
Common stock - $.01 par value, authorized 150,000 shares; issued: 108,713 and 108,422 shares, respectively; outstanding: 104,121 and 103,952 shares, respectively	1,087	1,084
Additional paid-in capital	1,154,182	1,148,196
Retained earnings	708,568	878,516
Accumulated other comprehensive loss	(204,467)	(184,240)
Total stockholders' equity including treasury stock	1,659,370	1,843,556
Less: Treasury stock, at cost, 4,592 and 4,470 shares, respectively	(109,578)	(106,507)
Total stockholders’ equity	1,549,792	1,737,049
Total liabilities and stockholders’ equity	$ 2,778,271	$ 2,946,674

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts (in dollars)	$ 405	$ 1,828
Preferred stock, par value (USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	108,713,000	108,422,000
Common stock, shares, outstanding	104,121,000	103,952,000
Treasury stock, shares	4,592,000	4,470,000

Consolidated Statements Of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Net sales	$ 599,797	$ 632,720	$ 1,744,786	$ 1,838,171
Cost of sales	474,528	499,707	1,405,650	1,447,820
Gross profit	125,269	133,013	339,136	390,351
Selling, general and administrative expenses	87,739	86,063	255,383	258,586
Amortization of acquired intangibles	3,802	4,713	11,567	13,859
Project Terra costs and other	9,408	4,831	29,613	13,750
Chief Executive Officer Succession Plan expense, net	455	0	30,156	0
Accounting review and remediation costs, net of insurance proceeds	0	3,313	4,334	6,406
Long-lived asset and intangibles impairment	0	4,839	23,709	8,290
Operating income (loss)	23,865	29,254	(15,626)	89,460
Interest and other financing expense, net	9,390	6,782	25,912	19,543
Other expense/(income), net	1,068	(1,560)	2,041	(5,447)
Income (loss) from continuing operations before income taxes and equity in net loss (income) of equity-method investees	13,407	24,032	(43,579)	75,364
Provision (benefit) for income taxes	3,114	(1,310)	(1,679)	(11,516)
Equity in net loss (income) of equity-method investees	205	101	391	(104)
Net income (loss) from continuing operations	10,088	25,241	(42,291)	86,984
Net loss from discontinued operations, net of tax	(75,925)	(12,555)	(127,472)	(7,349)
Net (loss) income	$ (65,837)	$ 12,686	$ (169,763)	$ 79,635
Net (loss) income per common share:
Basic net income (loss) per common share from continuing operations (USD per share)	$ 0.10	$ 0.24	$ (0.41)	$ 0.84
Basic net income (loss) per common share from discontinued operations (USD per share)	(0.73)	(0.12)	(1.23)	(0.07)
Basic net income (loss) per common share (USD per share)	(0.63)	0.12	(1.63)	0.77
Diluted net income (loss) per common share from continuing operations (USD per share)	0.10	0.24	(0.41)	0.83
Diluted net income (loss) per common share from discontinued operations (USD per share)	(0.73)	(0.12)	(1.23)	(0.07)
Diluted net income (loss) per common share (USD per share)	$ (0.63)	$ 0.12	$ (1.63)	$ 0.76
Shares used in the calculation of net (loss) income per common share:
Basic (shares)	104,117	103,918	104,045	103,821
Diluted (shares)	104,334	104,503	104,045	104,473

Consolidated Statements Of Comprehensive (Loss) Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (65,837)	$ 12,686	$ (169,763)	$ 79,635
Pre-tax amount
Foreign currency translation adjustments	20,934	37,868	(20,533)	80,065
Change in deferred (losses) gains on cash flow hedging instruments	(52)	0	(52)	(82)
Change in unrealized losses on equity investment	0	(68)	0	(70)
Total other comprehensive income (loss)	20,882	37,800	(20,585)	79,913
Tax (expense) benefit
Foreign currency translation adjustments	0	0	0	0
Change in deferred (losses) gains on cash flow hedging instruments	10	0	10	15
Change in unrealized losses on equity investment	0	(33)	0	(33)
Total other comprehensive income (loss)	10	(33)	10	(18)
After-tax amount
Foreign currency translation adjustments	20,934	37,868	(20,533)	80,065
Change in deferred (losses) gains on cash flow hedging instruments	(42)	0	(42)	(67)
Change in unrealized losses on equity investment	0	(101)	0	(103)
Net change in accumulated other comprehensive income (loss)	20,892	37,767	(20,575)	79,895
Total comprehensive (loss) income	$ (44,945)	$ 50,453	$ (190,338)	$ 159,530

Consolidated Statement Of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Jun. 30, 2017	$ 1,712,832	$ 1,080	$ 1,137,724	$ 868,822	$ (99,315)	$ (195,479)
Balance, shares at Jun. 30, 2017		107,989			4,287
Increase (Decrease) in Stockholders' Equity
Net income	19,846			19,846
Other comprehensive loss	33,787					33,787
Issuance of common stock pursuant to stock-based compensation plans	0	$ 1	(1)
Issuance of common stock pursuant to stock-based compensation plans, shares		98
Shares withheld for payment of employee payroll taxes due on shares issued under stock-based compensation plans	(2,098)				$ (2,098)
Shares withheld for payment of employee payroll taxes due on shares issued under stock based compensation plans, shares					52
Stock-based compensation expense	3,164		3,164
Balance at Sep. 30, 2017	1,767,531	$ 1,081	1,140,887	888,668	$ (101,413)	(161,692)
Balance, shares at Sep. 30, 2017		108,087			4,339
Balance at Jun. 30, 2017	1,712,832	$ 1,080	1,137,724	868,822	$ (99,315)	(195,479)
Balance, shares at Jun. 30, 2017		107,989			4,287
Increase (Decrease) in Stockholders' Equity
Net income	79,635
Other comprehensive loss	79,895
Balance at Mar. 31, 2018	1,875,767	$ 1,084	1,147,978	948,457	$ (106,168)	(115,584)
Balance, shares at Mar. 31, 2018		108,383			4,458
Balance at Sep. 30, 2017	1,767,531	$ 1,081	1,140,887	888,668	$ (101,413)	(161,692)
Balance, shares at Sep. 30, 2017		108,087			4,339
Increase (Decrease) in Stockholders' Equity
Net income	47,103			47,103
Other comprehensive loss	8,341					8,341
Issuance of common stock pursuant to stock-based compensation plans	0	$ 3	(3)
Issuance of common stock pursuant to stock-based compensation plans, shares		284
Shares withheld for payment of employee payroll taxes due on shares issued under stock-based compensation plans	(4,587)				$ (4,587)
Shares withheld for payment of employee payroll taxes due on shares issued under stock based compensation plans, shares					114
Stock-based compensation expense	4,158		4,158
Balance at Dec. 31, 2017	1,822,546	$ 1,084	1,145,042	935,771	$ (106,000)	(153,351)
Balance, shares at Dec. 31, 2017		108,371			4,453
Increase (Decrease) in Stockholders' Equity
Net income	12,686			12,686
Other comprehensive loss	37,767					37,767
Issuance of common stock pursuant to stock-based compensation plans	0	$ 0	0
Issuance of common stock pursuant to stock-based compensation plans, shares		12
Shares withheld for payment of employee payroll taxes due on shares issued under stock-based compensation plans	(168)				$ (168)
Shares withheld for payment of employee payroll taxes due on shares issued under stock based compensation plans, shares					5
Stock-based compensation expense	2,936		2,936
Balance at Mar. 31, 2018	1,875,767	$ 1,084	1,147,978	948,457	$ (106,168)	(115,584)
Balance, shares at Mar. 31, 2018		108,383			4,458
Balance at Jun. 30, 2018	$ 1,737,049	$ 1,084	1,148,196	878,516	$ (106,507)	(184,240)
Balance, shares at Jun. 30, 2018	108,422	108,422			4,470
Increase (Decrease) in Stockholders' Equity
Net income	$ (37,425)			(37,425)
Other comprehensive loss	(13,519)					(13,519)
Issuance of common stock pursuant to stock-based compensation plans	0	$ 1	(1)
Issuance of common stock pursuant to stock-based compensation plans, shares		85
Shares withheld for payment of employee payroll taxes due on shares issued under stock-based compensation plans	(979)				$ (979)
Shares withheld for payment of employee payroll taxes due on shares issued under stock based compensation plans, shares					35
Stock-based compensation expense	135		135
Balance at Sep. 30, 2018	1,685,424	$ 1,085	1,148,330	840,906	$ (107,486)	(197,411)
Balance, shares at Sep. 30, 2018		108,507			4,505
Balance at Jun. 30, 2018	$ 1,737,049	$ 1,084	1,148,196	878,516	$ (106,507)	(184,240)
Balance, shares at Jun. 30, 2018	108,422	108,422			4,470
Increase (Decrease) in Stockholders' Equity
Net income	$ (169,763)
Other comprehensive loss	(20,575)
Balance at Mar. 31, 2019	$ 1,549,792	$ 1,087	1,154,182	708,568	$ (109,578)	(204,467)
Balance, shares at Mar. 31, 2019	108,713	108,713			4,592
Balance at Sep. 30, 2018	$ 1,685,424	$ 1,085	1,148,330	840,906	$ (107,486)	(197,411)
Balance, shares at Sep. 30, 2018		108,507			4,505
Increase (Decrease) in Stockholders' Equity
Net income	(66,501)			(66,501)
Other comprehensive loss	(27,948)					(27,948)
Issuance of common stock pursuant to stock-based compensation plans	0	$ 2	(2)
Issuance of common stock pursuant to stock-based compensation plans, shares		184
Shares withheld for payment of employee payroll taxes due on shares issued under stock-based compensation plans	(1,943)				$ (1,943)
Shares withheld for payment of employee payroll taxes due on shares issued under stock based compensation plans, shares					79
Stock-based compensation expense	1,911		1,911
Balance at Dec. 31, 2018	1,590,943	$ 1,087	1,150,239	774,405	$ (109,429)	(225,359)
Balance, shares at Dec. 31, 2018		108,691			4,584
Increase (Decrease) in Stockholders' Equity
Net income	(65,837)			(65,837)
Other comprehensive loss	20,892					20,892
Issuance of common stock pursuant to stock-based compensation plans	0	$ 0	0
Issuance of common stock pursuant to stock-based compensation plans, shares		22
Shares withheld for payment of employee payroll taxes due on shares issued under stock-based compensation plans	(149)				$ (149)
Shares withheld for payment of employee payroll taxes due on shares issued under stock based compensation plans, shares					8
Stock-based compensation expense	3,943		3,943
Balance at Mar. 31, 2019	$ 1,549,792	$ 1,087	$ 1,154,182	$ 708,568	$ (109,578)	$ (204,467)
Balance, shares at Mar. 31, 2019	108,713	108,713			4,592

Consolidated Statement Of Stockholders' Equity (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017
Statement of Stockholders' Equity [Abstract]
Common stock, par value (USD per share)	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01

Consolidated Statements Of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income	$ (169,763)	$ 79,635
Net loss from discontinued operations	(127,472)	(7,349)
Net (loss) income from continuing operations	(42,291)	86,984
Adjustments to reconcile net (loss) income from continuing operations to net cash provided by operating activities from continuing operations:
Depreciation and amortization	42,074	45,139
Deferred income taxes	(24,653)	(30,115)
Chief Executive Officer Succession Plan expense, net	29,727	0
Equity in net loss (income) of equity-method investees	391	(104)
Stock-based compensation, net	5,931	10,258
Long-lived asset and intangibles impairment	23,709	8,290
Other non-cash items, net	3,703	(2,025)
Increase (decrease) in cash attributable to changes in operating assets and liabilities:
Accounts receivable	(8,824)	(23,998)
Inventories	(7,176)	(43,355)
Other current assets	315	(8,153)
Other assets and liabilities	5,248	5,367
Accounts payable and accrued expenses	(16,111)	19,082
Net cash provided by operating activities - continuing operations	12,043	67,370
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(55,892)	(48,368)
Acquisitions of businesses, net of cash acquired	0	(13,064)
Other	3,863	124
Net cash used in investing activities - continuing operations	(52,029)	(61,308)
CASH FLOWS FROM FINANCING ACTIVITIES
Borrowings under bank revolving credit facility	240,000	45,000
Repayments under bank revolving credit facility	(186,791)	(355,185)
Borrowings under term loan	0	299,245
Repayments under term loan	(11,250)	0
Funding of discontinued operations entities	(37,451)	(17,167)
(Repayments) borrowings of other debt, net	(4,770)	3,111
Shares withheld for payment of employee payroll taxes	(3,071)	(6,853)
Net cash used in financing activities - continuing operations	(3,333)	(31,849)
Effect of exchange rate changes on cash	(1,225)	5,884
Cash used in operating activities
Cash used in operating activities	(7,339)	(11,783)
Cash used in investing activities	(32,742)	(8,531)
Cash provided by financing activities	37,299	17,011
Net cash flows used in discontinued operations	(2,782)	(3,303)
Net decrease in cash and cash equivalents and restricted cash	(47,326)	(23,206)
Cash and cash equivalents at beginning of period	113,018	146,992
Cash and cash equivalents and restricted cash at end of period	65,692	123,786
Less: cash and cash equivalents of discontinued operations	(3,678)	(6,634)
Cash and cash equivalents and restricted cash of continuing operations at end of period	$ 62,014	$ 117,152

Business	9 Months Ended
Business	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	BUSINESS The Hain Celestial Group, Inc., a Delaware corporation (collectively, along with its subsidiaries, the “Company,” and herein referred to as “Hain Celestial,” “we,” “us” and “our”), was founded in 1993 and is headquartered in Lake Success, New York. The Company’s mission has continued to evolve since its founding, with health and wellness being the core tenet — To Create and Inspire A Healthier Way of Life^TM and be the leading marketer, manufacturer and seller of organic and natural, “better-for-you” products by anticipating and exceeding consumer expectations in providing quality, innovation, value and convenience. The Company is committed to growing sustainably while continuing to implement environmentally sound business practices and manufacturing processes. Hain Celestial sells its products through specialty and natural food distributors, supermarkets, natural food stores, mass-market and e-commerce retailers, food service channels and club, drug and convenience stores in over 80 countries worldwide. The Company manufactures, markets, distributes and sells organic and natural products under brand names that are sold as “better-for-you” products, providing consumers with the opportunity to lead A Healthier Way of Life™. Hain Celestial is a leader in many organic and natural products categories, with many recognized brands in the various market categories it serves, including Almond Dream^®, Arrowhead Mills^®, Bearitos^®, Better Bean^®, BluePrint^®, Casbah^®, Celestial Seasonings^®, Clarks™, Coconut Dream^®, Cully & Sully^®, Danival^®, DeBoles^®, Earth’s Best^®, Ella’s Kitchen^®, Europe’s Best^®, Farmhouse Fare™, Frank Cooper’s^®, Gale’s^®, Garden of Eatin’^®, GG UniqueFiber^®, Hain Pure Foods^®, Hartley’s^®, Health Valley^®, Imagine^®, Johnson’s Juice Co.™, Joya^®, Lima^®, Linda McCartney^® (under license), MaraNatha^®, Mary Berry (under license), Natumi^®, New Covent Garden Soup Co.^®, Orchard House^®, Rice Dream^®, Robertson’s^®, Rudi’s Gluten-Free Bakery™, Rudi’s Organic Bakery^®, Sensible Portions^®, Spectrum^®Organics, Soy Dream^®, Sun-Pat^®, Sunripe^®, SunSpire^®, Terra^®, The Greek Gods^®, Tilda^®, Walnut Acres^®, Yorkshire Provender^®, Yves Veggie Cuisine^®and William’s™. The Company’s personal care products are marketed under the Alba Botanica^®, Avalon Organics^®, Earth’s Best^®, JASON^®, Live Clean^® and Queen Helene^® brands.

Basis Of Presentation	9 Months Ended
Basis Of Presentation	Mar. 31, 2019
Accounting Policies [Abstract]
Basis Of Presentation	BASIS OF PRESENTATION The Company’s unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP. The amounts as of and for the periods ended June 30, 2018 are derived from the Company’s audited annual financial statements. The unaudited consolidated financial statements reflect all normal recurring adjustments which, in management’s opinion, are necessary for a fair presentation for interim periods. Operating results for the three and nine months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2019. Please refer to the Notes to the Consolidated Financial Statements as of June 30, 2018 and for the fiscal year then ended included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 (the “Form 10-K”) for information not included in these condensed notes. The Company is presenting the operating results and cash flows of the Hain Pure Protein reportable segment within discontinued operations in the current and prior periods. The assets and liabilities of the Hain Pure Protein reportable segment are presented as assets and liabilities of discontinued operations in the Consolidated Balance Sheets for all periods presented. All amounts in the unaudited consolidated financial statements, notes and tables have been rounded to the nearest thousand, except par values and per share amounts, unless otherwise indicated. Newly Adopted Accounting Pronouncements ASU 2014-09, Revenue from Contracts with Customers (Topic 606) In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). This guidance outlines a single, comprehensive model for accounting for revenue from contracts with customers, providing a single five-step model to be applied to all revenue transactions. The guidance also requires improved disclosures to assist users of the financial statements to better understand the nature, amount, timing and uncertainty of revenue that is recognized. Subsequent to the issuance of ASU 2014-09, the FASB issued various additional ASUs clarifying and amending this new revenue guidance. The Company adopted the new revenue standard on July 1, 2018 using the modified retrospective transition method. The adoption did not materially impact our results of operations or financial position, and, as a result, comparisons of revenues and operating profit between periods were not materially affected by the adoption of ASU 2014-09. The Company recorded a net increase to beginning retained earnings of $163 on July 1, 2018 due to the cumulative impact of adopting ASU 2014-09. Additionally, as our products exhibit similar economic characteristics, are sold through similar channels to similar customers and are recognized at a point in time, we have concluded that the Company’s segment disclosures in Note 17, Segment Information, are indicative of the level of revenue disaggregation required under ASU 2014-09. ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10) In January 2016, the FASB issued ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 requires that most equity investments be measured at fair value, with subsequent changes in fair value recognized in net income. The pronouncement also impacts financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. We adopted ASU 2016‑01 in the three months ended September 30, 2018, which resulted in a net decrease to beginning retained earnings of $348 on July 1, 2018, representing the accumulated unrealized losses (net of tax) reported in accumulated other comprehensive income (loss) for available-for-sale equity securities on June 30, 2018. We no longer classify equity investments as trading or available-for-sale and will no longer recognize unrealized holding gains and losses on equity securities previously classified as available-for-sale in other comprehensive income (loss) as a result of adoption of ASU 2016-01. Recently Issued Accounting Pronouncements Not Yet Effective In February 2016, the FASB issued ASU 2016-02, Leases (ASC 842). The amendments in this ASU replace most of the existing U.S. GAAP lease accounting guidance in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The ASU is effective for annual periods beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. The ASU requires lessees and lessors to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB approved amendments to create an optional transition method that will provide an option to use the effective date of ASC 842 as the date of initial application of the transition. Under the new transition method, a reporting entity would initially apply the new lease requirements at the effective date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption, continue to report comparative periods presented in the financial statements in the period of adoption in accordance with current U.S. GAAP (i.e., ASC 840, Leases) and provide the required disclosures under ASC 840 for all periods presented under current U.S. GAAP. We will adopt the standard effective July 1, 2019. As part of the Company’s assessment work to-date, the Company has formed an implementation work team to perform a comprehensive evaluation of the impact of the adoption of this guidance, which includes assessing the Company’s lease portfolio, the impact to business processes and internal controls over financial reporting and the related disclosure requirements. Additionally, the Company is implementing lease accounting software to assist in the quantification of the expected impact on the Consolidated Balance Sheet and to facilitate the calculations of the related accounting entries and disclosures, as well as to facilitate accounting, presentation and disclosure for all leases after the initial date of application under the new standard. While the Company is continuing to assess all potential impacts of the standard, the most significant impact relates to the recognition of new right-of-use assets and lease liabilities on the balance sheet for manufacturing, warehouse and office space operating leases. We believe that all of these leases will continue to be classified as operating leases under the new standard. We expect the accounting for capital leases to remain substantially unchanged. Refer to Note 2, Summary of Significant Accounting Policies and Practices, in the Notes to the Consolidated Financial Statements as of June 30, 2018 and for the fiscal year then ended included in the Form 10-K for a detailed discussion on additional recently issued accounting pronouncements not yet adopted by the Company. There has been no change to the statements made in the Form 10-K as of the date of filing of this Form 10-Q.

Chief Executive Officer Succession Plan	9 Months Ended
Chief Executive Officer Succession Plan	Mar. 31, 2019
Compensation Related Costs [Abstract]
Chief Executive Officer Succession Plan	CHIEF EXECUTIVE OFFICER SUCCESSION PLAN On June 24, 2018, the Company entered into a Chief Executive Officer (“CEO”) Succession Agreement (the “Succession Agreement”), whereby the Company’s former CEO, Irwin D. Simon, agreed to terminate his employment with the Company upon the hiring of a new CEO. On October 26, 2018, the Company’s Board of Directors appointed Mark L. Schiller as President and CEO, succeeding Mr. Simon. In connection with the appointment, on October 26, 2018, the Company and Mr. Schiller entered into an employment agreement, which was approved by the Board, with Mr. Schiller’s employment commencing on November 5, 2018. Accordingly, Mr. Simon’s employment with the Company terminated on November 4, 2018. Cash Separation Payments The Succession Agreement provides Mr. Simon with a cash separation payment of $34,295 payable in a single lump sum and cash benefit continuation costs of $208. These costs were recognized from June 24, 2018 through November 4, 2018. Expense recognized in connection with the agreement was $33,051 in the nine months ended March 31, 2019, and are included in the Consolidated Statement of Operations as a component of “Chief Executive Officer Succession Plan expense, net.” As of March 31, 2019, the total cash separation payment was held in a rabbi trust, which has been classified as restricted cash and included in accrued expenses and other current liabilities in the Consolidated Balance Sheet. The cash separation payment was paid on May 6, 2019. Consulting Agreement On October 26, 2018, the Company and Mr. Simon entered into a Consulting Agreement (the “Consulting Agreement”) in order to, among other things, assist Mr. Schiller with his transition as the Company’s incoming CEO. The term of the Consulting Agreement commenced on November 5, 2018 and continued until February 5, 2019. Mr. Simon was entitled to receive an aggregate consulting fee of $975 as compensation for his services during the consulting term, of which $325 and $975 was recognized in the Consolidated Statement of Operations as a component of “Chief Executive Officer Succession Plan expense, net” in the three and nine months ended March 31, 2019, respectively.

Earnings (Loss) Per Share

9 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Earnings (Loss) Per Share

EARNINGS (LOSS) PER SHARE

The following table sets forth the computation of basic and diluted net (loss) income per share:



	Three Months Ended March 31,						Nine Months Ended March 31,
	2019			2018			2019			2018
Numerator:
Net income (loss) from continuing operations	$	10,088		$	25,241		$	(42,291	)	$	86,984
Net loss from discontinued operations, net of tax	(75,925		)	(12,555		)	(127,472		)	(7,349		)
Net (loss) income	$	(65,837	)	$	12,686		$	(169,763	)	$	79,635

Denominator:
Basic weighted average shares outstanding	104,117			103,918			104,045			103,821
Effect of dilutive stock options, unvested restricted stock and unvested restricted share units	217			585			—			652
Diluted weighted average shares outstanding	104,334			104,503			104,045			104,473

Basic net (loss) income per common share:
Continuing operations	$	0.10		$	0.24		$	(0.41	)	$	0.84
Discontinued operations	(0.73		)	(0.12		)	(1.23		)	(0.07		)
Basic net (loss) income per common share	$	(0.63	)	$	0.12		$	(1.63	)	$	0.77

Diluted net (loss) income per common share:
Continuing operations	$	0.10		$	0.24		$	(0.41	)	$	0.83
Discontinued operations	(0.73		)	(0.12		)	(1.23		)	(0.07		)
Diluted net (loss) income per common share	$	(0.63	)	$	0.12		$	(1.63	)	$	0.76

Basic net (loss) income per share excludes the dilutive effects of stock options, unvested restricted stock and unvested restricted share units.

Due to our net loss in the nine months ended March 31, 2019, all common stock equivalents such as stock options and unvested restricted stock awards have been excluded from the computation of diluted net loss per share because the effect would have been anti-dilutive to the computations. Diluted earnings per share for the three months ended March 31, 2019 and the three and nine months ended March 31, 2018 includes the dilutive effects of common stock equivalents such as stock options and unvested restricted stock awards.

There were 3,071 and 3,117 stock-based awards excluded from our diluted net (loss) income per share calculations for the three and nine months ended March 31, 2019, respectively, as such awards were contingently issuable based on market or performance conditions, and such conditions had not been achieved during the respective periods. Contingently issuable awards excluded were 559 for each of the three and nine months ended March 31, 2018, respectively.

There were 273 and 621 restricted stock awards excluded from our diluted net (loss) income per share calculation for the three and nine months ended March 31, 2019, as such awards were anti-dilutive. Anti-dilutive restricted stock awards excluded from our diluted earnings per share calculation for the three and nine months ended March 31, 2018 were de minimis.

There were 110 potential shares of common stock issuable upon exercise of stock options excluded from our diluted net loss per share calculation for the nine months ended March 31, 2019, as they were anti-dilutive due to the net loss recorded in the period. No such awards were excluded for the three months ended March 31, 2019 and the three and nine months ended March 31, 2018.

Share Repurchase Program

On June 21, 2017, the Company's Board of Directors authorized the repurchase of up to $250,000 of the Company’s issued and outstanding common stock. Repurchases may be made from time to time in the open market, pursuant to pre-set trading plans, in private transactions or otherwise. The authorization does not have a stated expiration date. The extent to which the Company repurchases its shares and the timing of such repurchases will depend upon market conditions and other corporate considerations, including the Company’s historical strategy of pursuing accretive acquisitions. As of March 31, 2019, the Company had not repurchased any shares under this program and had $250,000 of remaining capacity under the share repurchase program.

Discontinued Operations

9 Months Ended

Mar. 31, 2019

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

DISCONTINUED OPERATIONS

In March 2018, the Company’s Board of Directors approved a plan to sell all of the operations of the Hain Pure Protein Corporation (“HPPC”) and EK Holdings, Inc. (“Empire”) operating segments, which were reported in the aggregate as the Hain Pure Protein reportable segment. Collectively, these planned dispositions represent a strategic shift that will have a major impact on the Company’s operations and financial results and have been accounted for as discontinued operations.

The Company is presenting the operating results and cash flows of Hain Pure Protein within discontinued operations in the current and prior periods. The assets and liabilities of Hain Pure Protein are presented as assets and liabilities of discontinued operations in the Consolidated Balance Sheets for all periods presented.

Sale of Plainville Farms Business

On February 15, 2019, the Company completed the sale of substantially all of the assets used primarily for the Plainville Farms business (a component of HPPC), which included $25,000 in cash to the purchaser, for a nominal purchase price. In addition, the purchaser assumed the current liabilities on the balance sheet of the Plainville Farms business as of the closing date. As a condition to consummating the sale, the Company entered into a Contingent Funding and Earnout Agreement, which provides for the issuance by the Company of an irrevocable stand-by letter of credit of $10,000 which expires nineteen months after issuance. The Company is entitled to receive an earnout not to exceed, in the aggregate, 120% of the maximum amount that the purchaser draws on the letter of credit at any point from the date of issuance through the expiration of the letter of credit. Earnout payments are based on a specified percentage of annual free cash flow achieved for all fiscal years ending on or prior to June 30, 2026. If a change in control of the purchaser occurs prior to June 30, 2026, the purchaser will pay the Company 120% of the difference between the amount drawn on the letter of credit less the sum of all earnout payments made prior to such time up to the net proceeds received by the purchaser. At March 31, 2019, the Company had not recorded an asset associated with the earnout. As a result of the disposition, the Company recognized a pre-tax loss on sale of $40,223, or $29,685 net of tax, in the three months ended March 31, 2019 to write down the assets and liabilities to the final sales price less costs to sell.

On May 8, 2019, the Company entered into a definitive agreement to sell all of its equity interest in Hain Pure Protein Corporation, which includes the FreeBird™ and Empire® Kosher businesses, for a purchase price of $80,000, subject to adjustments. The transaction is expected to close before June 30, 2019, the end of the Company's fiscal year.

The following table presents the major classes of Hain Pure Protein’s line items constituting the “Net loss from discontinued operations, net of tax” in our Consolidated Statements of Operations:



	Three Months Ended March 31,						Nine Months Ended March 31,
	2019			2018			2019			2018
Net sales	$	88,729		$	118,198		$	349,449		$	396,227
Cost of sales	88,277			113,629			356,073			373,122
Gross profit (loss)	452			4,569			(6,624		)	23,105
Selling, general and administrative expense	4,039			5,888			13,031			14,458
Asset impairments ⁽¹⁾	51,348			—			109,252			—
Other expense	2,182			805			7,377			3,258
Loss on sale of discontinued operations	40,223			—			40,223			—
Net (loss) income from discontinued operations before income taxes	(97,340		)	(2,124		)	(176,507		)	5,389
(Benefit) provision for income taxes	(21,415		)	10,431			(49,035		)	12,738
Net loss from discontinued operations, net of tax	$	(75,925	)	$	(12,555	)	$	(127,472	)	$	(7,349	)

Assets and liabilities of discontinued operations presented in the Consolidated Balance Sheets as of March 31, 2019 and June 30, 2018 are included in the following table:



	March 31,			June 30,
ASSETS	2019			2018
Cash and cash equivalents	$	3,678		$	6,461
Accounts receivable, less allowance for doubtful accounts	11,680			21,616
Inventories	31,600			105,359
Prepaid expenses and other current assets	1,906			5,604
Property, plant and equipment, net	49,537			83,776
Goodwill	41,089			41,089
Trademarks and other intangible assets, net	33,762			51,029
Other assets	2,636			4,381
Deferred tax assets ⁽²⁾	37,925			—
Impairments of long-lived assets held for sale⁽¹⁾	(77,632		)	(78,464		)
Current assets of discontinued operations⁽³⁾	$	136,181		$	240,851

LIABILITIES
Accounts payable	$	11,211		$	31,762
Accrued expenses and other current liabilities	3,914			6,880
Deferred tax liabilities ⁽²⁾	—			11,111
Other noncurrent liabilities	70			93
Current liabilities of discontinued operations⁽³⁾	$	15,195		$	49,846

(1) In the nine months ended March 31, 2019 the Company recorded asset impairment charges of $109,252, of which $51,348 was recorded in the third quarter of fiscal 2019 to adjust the carrying value of the Hain Pure Protein reportable segment to its estimated selling price.

(2) The change in deferred taxes from June 30, 2018 to March 31, 2019 was the result of the reversal of the $12,250 deferred tax liability previously recorded related to Hain Pure Protein being classified as held for sale. In addition, deferred taxes were impacted by the tax effect of current period book losses as well as the deferred tax benefit arising from asset impairment charges.

(3) The assets and liabilities of Hain Pure Protein are classified as current on the March 31, 2019 and June 30, 2018 Consolidated Balance Sheets because it is probable that the sale will occur within the three months ended June 30, 2019.

Acquisitions	9 Months Ended
Acquisitions	Mar. 31, 2019
Business Combinations [Abstract]
Acquisitions	ACQUISITIONS The Company accounts for acquisitions in accordance with ASC 805, Business Combinations. The results of operations of the acquisitions have been included in the consolidated results from their respective dates of acquisition. The purchase price of each acquisition is allocated to the tangible assets, liabilities and identifiable intangible assets acquired based on their estimated fair values. Acquisitions may include contingent consideration, the fair value of which is estimated on the acquisition date as the present value of the expected contingent payments, determined using weighted probabilities of possible payments. The fair values assigned to identifiable intangible assets acquired were determined primarily by using an income approach which was based on assumptions and estimates made by management. Significant assumptions utilized in the income approach were based on Company-specific information and projections which are not observable in the market and are thus considered Level 3 measurements as defined by authoritative guidance. The excess of the purchase price over the fair value of the identified assets and liabilities has been recorded as goodwill. The costs related to all acquisitions have been expensed as incurred and are included in “Project Terra costs and other” in the Consolidated Statements of Operations. Acquisition-related costs for the three and nine months ended March 31, 2019 were de minimis. Acquisition-related costs of $8 and $336 were expensed in the three and nine months ended March 31, 2018, respectively. The expenses incurred primarily related to professional fees and other transaction-related costs associated with our recent acquisitions. Fiscal 2019 There were no acquisitions completed in the nine months ended March 31, 2019. Fiscal 2018 On December 1, 2017, the Company acquired Clarks UK Limited, (“Clarks”), a leading maple syrup and natural sweetener brand in the United Kingdom. Clarks produces natural sweeteners under the Clarks^TM brand, including maple syrup, honey and carob, date and agave syrups, which are sold in leading retailers and used by food service and industrial customers in the United Kingdom. Consideration for the transaction, inclusive of a subsequent working capital adjustment, consisted of cash, net of cash acquired, totaling £9,179 (approximately $12,368 at the transaction date exchange rate). Additionally, contingent consideration of up to a maximum of £1,500 is payable based on the achievement of specified operating results over the 18-month period following completion of the acquisition. Clarks is included in our United Kingdom operating segment. Net sales and income before income taxes attributable to the Clarks acquisition included in our consolidated results represented less than 1% of our consolidated results for the three and nine months ended March 31, 2019 and 2018.

Inventories

9 Months Ended

Mar. 31, 2019

Inventory Disclosure [Abstract]

Inventories

INVENTORIES

Inventories consisted of the following:



	March 31, 2019		June 30, 2018
Finished goods	$	235,232	$	231,926
Raw materials, work-in-progress and packaging	160,014		159,599
	$	395,246	$	391,525

Property, Plant And Equipment, Net

9 Months Ended

Mar. 31, 2019

Property, Plant and Equipment [Abstract]

Property, Plant And Equipment, Net

PROPERTY, PLANT AND EQUIPMENT, NET

Property, plant and equipment, net consisted of the following:



	March 31, 2019		June 30, 2018
Land	$	28,049	$	28,378
Buildings and improvements	95,604		83,289
Machinery and equipment	315,574		323,348
Computer hardware and software	56,168		54,092
Furniture and fixtures	18,624		17,894
Leasehold improvements	31,269		31,519
Construction in progress	30,556		17,280
	575,844		555,800
Less: Accumulated depreciation and amortization	244,774		245,628
	$	331,070	$	310,172

Depreciation and amortization expense for the three months ended March 31, 2019 and 2018 was $8,110 and $8,212, respectively. Such expense for the nine months ended March 31, 2019 and 2018 was $24,294 and $24,580, respectively.

In the nine months ended March 31, 2019, the Company recorded $5,809 of non-cash impairment charges primarily related to the Company’s decision to consolidate manufacturing of certain fruit-based products in the United Kingdom.

There were no impairment charges recorded in the three months ended March 31, 2019.

Goodwill And Other Intangible Assets

9 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill And Other Intangible Assets

GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill

The following table shows the changes in the carrying amount of goodwill by business segment:



	United States		United Kingdom			Rest of World			Total
Balance as of June 30, 2018 ^(a)	$	552,814	$	377,163		$	94,159		$	1,024,136
Translation and other adjustments, net	—		(5,203		)	(2,070		)	(7,273		)
Balance as of March 31, 2019^(a)	$	552,814	$	371,960		$	92,089		$	1,016,863

(a) The total carrying value of goodwill is reflected net of $134,277 of accumulated impairment charges, of which $97,358 related to the Company’s United Kingdom operating segment, $29,219 related to the Company’s Europe operating segment and $7,700 related to the Company’s Hain Ventures operating segment (formerly known as the Cultivate operating segment).

Beginning in the third quarter of fiscal 2018, operations of Hain Pure Protein have been classified as discontinued operations as discussed in Note 5, Discontinued Operations. Therefore, goodwill associated with Hain Pure Protein is presented as current assets of discontinued operations in the Consolidated Financial Statements.

The Company performs its annual test for goodwill and indefinite-lived intangible asset impairment as of the first day of the fourth quarter of its fiscal year. In addition, if and when events or circumstances change that would more likely than not reduce the fair value of any of its reporting units or indefinite-life intangible assets below their carrying value, an interim test is performed.

During the three months ended December 31, 2018, the Company updated the forecasted operating results for each of its reporting units based on the most recent financial results. The updated forecasts reflected lower projected short-term revenue growth and profitability than previously expected, primarily in its United States segment. In connection with the preparation of the Consolidated Financial Statements for the period ended December 31, 2018, the Company assessed qualitative and quantitative factors, which included sensitivity analyses, and concluded that it is more likely than not that the fair value of its reporting units exceeded its carrying amount.

There were no events or circumstances that warranted an interim impairment test for goodwill during the three months ended March 31, 2019. The Company will continue to monitor impairment indicators and financial results in future periods.

Other Intangible Assets

The following table sets forth Consolidated Balance Sheet information for intangible assets, excluding goodwill, subject to amortization and intangible assets not subject to amortization:



	March 31, 2019			June 30, 2018
Non-amortized intangible assets:
Trademarks and tradenames ^(a)	$	364,068		$	385,609
Amortized intangible assets:
Other intangibles	236,333			239,323
Less: accumulated amortization	(124,819		)	(114,545		)
Net carrying amount	$	475,582		$	510,387

(a) The gross carrying value of trademarks and tradenames is reflected net of $83,734 and $65,834 of accumulated impairment charges at March 31, 2019 and at June 30, 2018, respectively.

Indefinite-lived intangible assets, which are not amortized, consist primarily of acquired tradenames and trademarks. Indefinite-lived intangible assets are evaluated on an annual basis in conjunction with the Company’s evaluation of goodwill, or on an interim basis if and when events or circumstances change that would more likely than not reduce the fair value of any of its indefinite-life intangible assets below their carrying value. In assessing fair value, the Company utilizes a “relief from royalty” methodology. This approach involves two steps: (i) estimating the royalty rates for each trademark and (ii) applying these royalty rates to a projected net sales stream and discounting the resulting cash flows to determine fair value. If the carrying value of the indefinite-lived intangible asset exceeds the fair value of the asset, the carrying value is written down to fair value in the period identified. During the three months ended December 31, 2018, the Company determined that an indicator of impairment existed in certain of the Company’s indefinite-lived tradenames. The result of this assessment for the second quarter of fiscal 2019 indicated that the fair value of certain of the Company’s tradenames was below their carrying value, and therefore an impairment charge of $17,900 was recognized ($11,300 in the United States segment, $2,787 in the United Kingdom segment and $3,813 in the Rest of World). During the fiscal year ended June 30, 2018, an impairment charge of $5,632 ($5,100 in the Rest of World and $532 in the United Kingdom segment) related to certain of the Company’s tradenames was recognized.

There were no events or circumstances that warranted an interim impairment test for indefinite-lived intangible assets during the three months ended March 31, 2019.

Amortized intangible assets, which are deemed to have a finite life, primarily consist of customer relationships and are amortized over their estimated useful lives of 3 to 25 years. Amortization expense included in continuing operations was as follows:



	Three Months Ended March 31,				Nine Months Ended March 31,
	2019		2018		2019		2018
Amortization of acquired intangibles	$	3,802	$	4,713	$	11,567	$	13,859

Debt And Borrowings

9 Months Ended

Mar. 31, 2019

Debt Disclosure [Abstract]

Debt And Borrowings

DEBT AND BORROWINGS

Debt and borrowings consisted of the following:



	March 31, 2019			June 30, 2018
Revolving credit facility	$	455,206		$	401,852
Term loan	285,000			296,250
Less: Unamortized issuance costs	(579		)	(692		)
Tilda short-term borrowing arrangements	6,654			9,338
Other borrowings	5,442			7,358
	751,723			714,106
Short-term borrowings and current portion of long-term debt	22,522			26,605
Long-term debt, less current portion	$	729,201		$	687,501

Credit Agreement

On February 6, 2018, the Company entered into the Third Amended and Restated Credit Agreement (the “Credit Agreement”). The Credit Agreement provides for a $1,000,000 revolving credit facility through February 6, 2023 and provides for a $300,000 term loan. Under the Credit Agreement, the revolving credit facility may be increased by an additional uncommitted $400,000, provided certain conditions are met.

Borrowings under the Credit Agreement may be used to provide working capital, finance capital expenditures and permitted acquisitions, refinance certain existing indebtedness and for other lawful corporate purposes. The Credit Agreement provides for multicurrency borrowings in Euros, Pounds Sterling and Canadian Dollars as well as other currencies which may be designated. In addition, certain wholly-owned foreign subsidiaries of the Company may be designated as co-borrowers. The Credit Agreement contains restrictive covenants, which are usual and customary for facilities of its type, and include, with specified exceptions, limitations on the Company’s ability to engage in certain business activities, incur debt, have liens, make capital expenditures, pay dividends or make other distributions, enter into affiliate transactions, consolidate, merge or acquire or dispose of assets, and make certain investments, acquisitions and loans. The Credit Agreement also requires the Company to satisfy certain financial covenants. On the date the Credit Agreement was consummated, these covenants included maintaining a consolidated interest coverage ratio (as defined in the Credit Agreement) of no less than 4.0 to 1.0 and a consolidated leverage ratio (as defined in the Credit Agreement) of no more than 3.5 to 1.0. The consolidated leverage ratio was initially subject to a step-up to 4.0 to 1.0 for the four full fiscal quarters following an acquisition. Obligations under the Credit Agreement are guaranteed by certain existing and future domestic subsidiaries of the Company. As of March 31, 2019, there were $455,206 and $285,000 of borrowings outstanding under the revolving credit facility and term loan, respectively, and $16,224 letters of credit outstanding under the Credit Agreement.

On November 7, 2018, the Company amended the Credit Agreement to modify the calculation of the consolidated leverage ratio related to costs associated with CEO succession as well as the Project Terra cost reduction programs.

On February 6, 2019, the Company entered into an amendment to the Credit Agreement, whereby its allowable consolidated leverage ratio increased to no more than 4.0 to 1.0 as of December 31, 2018 and no more than 3.75 to 1.0 as of March 31, 2019 and June 30, 2019. Under the terms of the February 6, 2019 amendment, the consolidated leverage ratio would return to 3.5 to 1.0 beginning in the period ending September 30, 2019.

On May 8, 2019, the Company entered into the Third Amendment to the Third Amended and Restated Credit Agreement (the “Amended Credit Agreement”), whereby, among other things, its allowable consolidated leverage ratio increased to no more than 5.0 to 1.0 from March 31, 2019 to December 31, 2019, no more than 4.75 to 1.0 at March 31, 2020, no more than 4.25 to 1.0 at June 30, 2020 and no more than 4.0 to 1.0 on September 30, 2020 and thereafter. The allowable consolidated leverage ratio for each period will be decreased by 0.25 upon sale of the Company’s remaining Hain Pure Protein business. Additionally, the Company’s required consolidated interest coverage ratio (as defined in the Credit Agreement) was reduced to no less than 3.0 to 1 through March 31, 2020, no less than 3.75 to 1 through March 31, 2021 and no less than 4.0 to 1 thereafter. As part of the Amended Credit Agreement, HPPC was released from its obligations as a borrower and a guarantor under the Credit Agreement.

The Amended Credit Agreement also required that the Company and the subsidiary guarantors enter into a Security and Pledge Agreement pursuant to which all of the obligations under the Amended Credit Agreement are secured by liens on assets of the Company and its material domestic subsidiaries, including stock of each of their direct subsidiaries and intellectual property, subject to agreed upon exceptions.

As of March 31, 2019, $528,570 is available under the Amended Credit Agreement, and the Company was in compliance with all associated covenants, as amended by the Amended Credit Agreement.

The Amended Credit Agreement provides that loans will bear interest at rates based on (a) the Eurocurrency Rate, as defined in the Credit Agreement, plus a rate ranging from 0.875% to 2.50% per annum; or (b) the Base Rate, as defined in the Credit Agreement, plus a rate ranging from 0.00% to 1.50% per annum, the relevant rate being the Applicable Rate. The Applicable Rate will be determined in accordance with a leverage-based pricing grid, as set forth in the Amended Credit Agreement. Swing line loans and Global Swing Line loans denominated in U.S. dollars will bear interest at the Base Rate plus the Applicable Rate, and Global Swing Line loans denominated in foreign currencies shall bear interest based on the overnight Eurocurrency Rate for loans denominated in such currency plus the Applicable Rate. The weighted average interest rate on outstanding borrowings under the Amended Credit Agreement at March 31, 2019 was 4.30%. Additionally, the Amended Credit Agreement contains a Commitment Fee, as defined in the Amended Credit Agreement, on the amount unused under the Amended Credit Agreement ranging from 0.20% to 0.45% per annum, and such Commitment Fee is determined in accordance with a leverage-based pricing grid.

The term loan has required installment payments due on the last day of each fiscal quarter commencing June 30, 2018 in an amount equal to $3,750 and can be prepaid in whole or in part without premium or penalty.

Tilda Short-Term Borrowing Arrangements

Tilda, a component of our United Kingdom reportable segment, maintains short-term borrowing arrangements primarily used to fund the purchase of rice from India and other countries. The maximum borrowings permitted under all such arrangements are £52,000. Outstanding borrowings are collateralized by the current assets of Tilda, typically have six-month terms and bear interest at variable rates typically based on LIBOR plus a margin (weighted average interest rate of approximately 3.27% at March 31, 2019). As of March 31, 2019 and June 30, 2018, there were $6,654 and $9,338 of borrowings under these arrangements, respectively.

Income Taxes	9 Months Ended
Income Taxes	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES In general, the Company uses an estimated annual effective tax rate, which is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. In the first quarter of fiscal 2019, the Company used an estimated annual effective tax rate to calculate its provision for income taxes. For the quarters ended March 31, 2019 and December 31, 2018, the Company calculated its effective tax rate on a discrete basis due to significant variations in the relationship between tax expense and projected pre-tax income. The Company’s effective tax rate may change from period-to-period based on recurring and non-recurring factors including the geographical mix of earnings, enacted tax legislation, state and local income taxes and tax audit settlements. On December 22, 2017, the U.S. government enacted comprehensive tax legislation pursuant to the Tax Cuts and Jobs Act (the “Tax Act”), which significantly revised the ongoing U.S. corporate income tax law by lowering the U.S. federal corporate income tax rate from 35% to 21%, implementing a territorial tax system, imposing a one-time tax on foreign unremitted earnings and setting limitations on deductibility of certain costs (e.g., interest expense and executive compensation), among other things. Due to the complexities involved in accounting for the Tax Act, the U.S. Securities and Exchange Commission’s Staff Accounting Bulletin (“SAB”) 118 required that the Company include in its financial statements a reasonable estimate of the impact of the Tax Act on earnings to the extent such reasonable estimate has been determined. Pursuant to SAB 118, the Company was allowed a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts. As of December 31, 2018, the Company finalized its accounting for the income tax effects of the Tax Act and recorded an additional expense of $8,205 related to its transition tax liability. The net increase in the transition tax was due to the finalization of the Company’s earnings and profits study for our foreign subsidiaries. The adjustment of the Company’s provisional tax expense was recorded as a change in estimate in accordance with SAB No. 118. Despite the completion of the Company’s accounting for the Tax Act under SAB 118, many aspects of the law remain unclear, and we expect ongoing guidance to be issued at both the federal and state levels. There was no new guidance issued in the third quarter of fiscal 2019 that impacted the Company’s liability. The Company will continue to monitor and assess the impact of any new developments. The Tax Act also includes a provision to tax global intangible low-taxed income (“GILTI”) of foreign subsidiaries. The FASB Staff Q&A Topic No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election either to recognize deferred taxes for temporary differences that are expected to reverse as GILTI in future years or provide for the tax expense related to GILTI resulting from those items in the year the tax is incurred. We have elected to recognize the resulting tax on GILTI as a period expense in the period the tax is incurred. We have computed the impact on our effective tax rate on a discrete basis. The effective income tax rate from continuing operations was expense of 23.2% and a benefit of 5.5% for the three months ended March 31, 2019 and March 31, 2018, respectively. The effective income tax rate from continuing operations was a benefit of 3.9% and 15.3% for the nine months ended March 31, 2019 and March 31, 2018, respectively. The effective income tax rate from continuing operations for the three and nine months ended March 31, 2019 was impacted by provisions in the Tax Act including GILTI, finalization of the transition tax liability, and limitations on the deductibility of executive compensation. The effective income tax rate was also impacted by the geographical mix of earnings and state taxes. The effective rate for the three and nine months ended March 31, 2018 was primarily impacted by the enactment of the Tax Act on December 22, 2017, specifically the revalue of net deferred tax liabilities to the enacted 21% tax rate, repealing the deduction for domestic production activities, inclusion of the transition tax liability estimate and deductibility of executive officers’ compensation. The effective income tax rate from continuing operations for the three and nine months ended March 31, 2018 was also favorably impacted by the geographical mix of earnings, as well as a $3,754 benefit relating to the release of the Company’s domestic uncertain tax position as a result of the expiration of the statute of limitations. The income tax benefit from discontinued operations was $21,415 and $49,035 for the three and nine months ended March 31, 2019, while the income tax expense from discontinued operations was $10,431 and $12,738 for the three and nine months ended March 31, 2018. The benefit for income taxes for the nine months ended March 31, 2019 includes the reversal of the $12,250 deferred tax liability previously recorded related to Hain Pure Protein being classified as held for sale. In addition, the three and nine month tax benefit is impacted by the tax effect of current period book losses including the loss on the sale of Plainville Farms assets in the third quarter of fiscal 2019 as well as the deferred tax benefit arising from asset impairment charges.

Accumulated Other Comprehensive Income (Loss)

9 Months Ended

Mar. 31, 2019

Equity [Abstract]

Accumulated Other Comprehensive Income (Loss)

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

The following table presents the changes in accumulated other comprehensive income (loss):



	Three Months Ended March 31,						Nine Months Ended March 31,
	2019			2018			2019			2018
Foreign currency translation adjustments:
Other comprehensive income (loss) before reclassifications ⁽¹⁾	$	20,934		$	37,868		$	(20,533	)	$	80,065
Deferred (losses)/gains on cash flow hedging instruments:
Other comprehensive (loss) income before reclassifications	(42		)	—			(42		)	39
Amounts reclassified into income ⁽²⁾	—			—			—			(106		)
Unrealized gains/(losses) on equity investment:
Other comprehensive loss before reclassifications	—			(101		)	—			(103		)
Net change in accumulated other comprehensive income (loss)	$	20,892		$	37,767		$	(20,575	)	$	79,895

(1) Foreign currency translation adjustments included intra-entity foreign currency transactions that were of a long-term investment nature and were a net loss of $403 and a net gain of $670 for the three months ended March 31, 2019 and 2018, respectively, and a net loss of $875 and a net gain of $1,736 for the nine months ended March 31, 2019 and 2018, respectively.

(2) Amounts reclassified into income for deferred (losses)/gains on cash flow hedging instruments are recorded in “Cost of sales” in the Consolidated Statements of Operations and, before taxes, were $132 for the nine months ended March 31, 2018. There were no amounts reclassified into income for deferred (losses)/gains on cash flow hedging instruments for the three and nine months ended March 31, 2019 and for the three months ended March 31, 2018.

Stock-Based Compensation And Incentive Performance Plans

9 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation And Incentive Performance Plans

STOCK-BASED COMPENSATION AND INCENTIVE PERFORMANCE PLANS

The Company has two stockholder-approved plans, the Amended and Restated 2002 Long-Term Incentive and Stock Award Plan and the 2000 Directors Stock Plan, under which the Company’s officers, senior management, other key employees, consultants and directors may be granted options to purchase the Company’s common stock or other forms of equity-based awards. The Company also grants shares under its 2019 Equity Inducement Award Program to induce selected individuals to become employees of the Company.

Compensation cost and related income tax benefits recognized in the Consolidated Statements of Operations for stock-based compensation plans were as follows:



	Three Months Ended March 31,				Nine Months Ended March 31,
	2019		2018		2019		2018
Selling, general and administrative expense	$	3,937	$	2,936	$	5,502	$	10,258
Chief Executive Officer Succession Plan expense, net	—		—		429		—
Discontinued operations	6		—		58		—
Total compensation cost recognized for stock-based compensation plans	$	3,943	$	2,936	$	5,989	$	10,258
Related income tax benefit	$	470	$	971	$	765	$	3,391

In the nine months ended March 31, 2019, the Company recorded a benefit of $1,867 related to the reversal of expense associated with the TSR Grant under the 2017-2019 LTIP, as defined and discussed further below.

Restricted Stock

A summary of the restricted stock and restricted share unit activity for the nine months ended March 31, 2019 is as follows:



	Number of Shares and Units		Weighted Average Grant Date Fair Value (per share)
Non-vested restricted stock, restricted share units, and performance units at June 30, 2018	1,057		$	22.29
Granted	3,470		$	7.13
Vested	(291	)	$	26.50
Forfeited	(333	)	$	17.68
Non-vested restricted stock, restricted share units, and performance units at March 31, 2019	3,903		$	8.89



	Nine Months Ended March 31,
	2019		2018
Fair value of restricted stock and restricted share units granted	$	24,734	$	14,595
Fair value of shares vested	$	7,725	$	14,622
Tax benefit recognized from restricted shares vesting	$	3,331	$	4,970

At March 31, 2019, $24,083 of unrecognized stock-based compensation expense, net of estimated forfeitures, related to non-vested restricted stock awards was expected to be recognized over a weighted average period of approximately 2.3 years.

Stock Options

A summary of the stock option activity for the nine months ended March 31, 2019 is as follows:



	Number of Options	Weighted Average Exercise Price		Weighted Average Contractual Life (years)	Aggregate Intrinsic Value
Options outstanding and exercisable at June 30, 2018	122	$	2.26
Exercised	—	—
Options outstanding and exercisable at March 31, 2019	122	$	2.26	12.3	$	2,544

At March 31, 2019, there was no unrecognized compensation expense related to stock option awards.

Long-Term Incentive Plan

The Company maintains a long-term incentive program (the “LTI Plan”). The LTI Plan currently consists of four performance-based long-term incentive plans (the “2016-2018 LTIP”, “2017-2019 LTIP”, “2018-2020 LTIP” and “2019-2021 LTIP”) that provide for performance equity awards that can be earned over defined performance periods. Participants in the LTI Plan include certain of the Company’s executive officers and other key executives.

The Compensation Committee administers the LTI Plan and is responsible for, among other items, selecting the specific performance measures for awards and setting the target performance required to receive an award after the completion of the performance period. The Compensation Committee determines the specific payout to the participants. Any such stock-based awards shall be issued pursuant to and be subject to the terms and conditions of the Amended and Restated 2002 Long-Term Incentive and Stock Award Plan, as in effect and as amended from time-to-time, and the 2019 Equity Inducement Award Program, as applicable.

2019-2021 LTIP

Grants Made Pursuant to the Amended and Restated 2002 Long-Term Incentive and Stock Award Plan

On January 24, 2019, upon adoption of the 2019-2021 LTIP, the Compensation Committee granted 912 performance share units (“PSUs”), the achievement of which is dependent upon a defined calculation of relative total shareholder return (“TSR”) over the period from November 6, 2018 to November 6, 2021. The PSUs granted represent 100% of the targeted award, and will vest pursuant to the achievement of pre-established three-year compound annual TSR levels that are aligned with the CEO Inducement Grant. The number of shares actually issued will range from zero to 300% of the shares granted. No PSUs will vest if the three-year compound annual TSR is below 15%. Of the 912 PSUs issued, 451 are subject to a holding period of one year after the vesting date. As such, an illiquidity discount was applied to the grant date fair value for those shares subject to the one year holding period. The total grant date fair value with and without the illiquidity discount was estimated to be $5.99 and $5.26 per share, respectively. The total grant date fair value of this award was $5,132. Total compensation cost related to this PSU award was $432 in the three and nine months ended March 31, 2019.

The Company also issued 156 three-year time-based restricted share units under the 2019-2021 LTIP.

Grants Made Pursuant to the 2019 Equity Inducement Award Program

The primary purpose of the 2019 Equity Inducement Award Program is to further the long term stability and success of the Company by providing a program to reward selected individuals newly hired as employees of the Company with grants of inducement awards. Shares issued under this program are granted outside of the Amended and Restated 2002 Long-Term Incentive and Stock Award Plan.

In the three months ended March 31, 2019, the Compensation Committee granted 926 PSUs to selected individuals hired as employees of the Company, the achievement of which is dependent upon a defined calculation of relative TSR over the period from November 6, 2018 to November 6, 2021. The PSUs granted represent 300% of the targeted award and will vest pursuant to the achievement of pre-established three-year compound annual TSR levels, which are aligned with the CEO Inducement Grant.

The number of PSUs expected to be earned, based upon the achievement of the TSR market condition, is factored into the grant date Monte Carlo valuation. Compensation expense is recognized on a straight-line basis over the service period, regardless of the eventual number of PSUs that are earned based upon the market condition, provided that each grantee remains an employee at the end of the performance period. Compensation expense is reversed if at any time during the service period a grantee is no longer an employee. These PSUs are subject to a holding period of one year after the vesting date. As such, an illiquidity discount was applied to the grant date fair value.



Grant Date	Shares Issued	Fair Value Per Share		Grant Date Fair Value
February 19, 2019	739	$	1.79	$	1,324
March 29, 2019	187	$	3.01	563
Total	926			$	1,887

The total number of shares actually issued will range from zero to 926. No PSUs will vest if the three-year compound annual TSR is below 15%.

2018-2020 LTIP

Upon adoption of the 2018-2020 LTIP, the Compensation Committee granted 45 PSUs, the achievement of which is dependent upon a defined calculation of relative TSR over the period from January 24, 2019 to June 30, 2020. The total grant date fair value of this award was estimated to be $18.32 per share, or $819.

2016-2018 and 2017-2019 LTIP

Upon adoption of the 2016-2018 LTIP and 2017-2019 LTIP, the Compensation Committee granted PSUs to each participant, the achievement of which is dependent upon a defined calculation of relative TSR over the period from July 1, 2015 to June 30, 2018 and from July 1, 2017 to June 30, 2019 (the “TSR Grant”), respectively. The grant date fair value for these awards was separately estimated based on a Monte Carlo simulation that calculated the likelihood of goal attainment. Each performance unit translates into one unit of common stock. The TSR Grant represents half of each participant’s target award. The other half of the 2016-2018 LTIP and 2017-2019 LTIP is based on the Company’s achievement of specified net sales growth targets over the respective three-year period. If the targets are achieved, the award in connection with the 2017-2019 LTIP may be paid only in unrestricted shares of the Company’s common stock.

During the three months ended September 30, 2018, in connection with the 2016-2018 LTIP, for the three-year performance period of July 1, 2015 through June 30, 2018, the Compensation Committee determined that the adjusted operating income goal required to be met for Section 162(m) funding was not achieved and determined that no awards would be paid or vested pursuant to the 2016-2018 LTIP. Accordingly, the 223 unvested performance stock unit awards previously granted in connection with the relative TSR portion of the award were forfeited, and amounts accrued relating to the net sales portion of the award were reversed. As such, in the three months ended September 30, 2018, the Company recorded a benefit of $6,482 associated with the reversal of previously accrued amounts under the net sales portion of the 2016-2018 LTIP, of which $5,065 was recorded in Chief Executive Officer Succession Plan expense, net on the Consolidated Statement of Operations.

In connection with the 2017-2019 LTIP, in the three months ended September 30, 2018, the Company determined that the achievement of the adjusted operating income goal required to be met for Section 162(m) funding was not probable. Accordingly, during the three months ended September 30, 2018, the Company recorded benefits of $1,129 and $1,867 associated with the reversal of previously accrued amounts under the portions of the 2017-2019 LTIP that were dependent on the achievement of pre-determined performance measures of net sales and relative TSR, respectively.

Other Grants

In the nine months ended March 31, 2019, the Company granted 201 time-based restricted share units to certain key employees and members of the Company’s Board of Directors that vest primarily over three years. Additionally, the Company issued 101 PSUs to certain key executives vesting over a period of one to two years based upon the achievement of certain market and/or performance based metrics being met.

CEO Inducement Grant

On November 6, 2018, Mr. Schiller received an award of 1,050 PSUs intended to represent the total three-year long-term incentive opportunity that would have been made in fiscal years 2019 – 2021. The PSUs will vest pursuant to the achievement of pre-established three-year compound annual TSR levels. The number of shares actually issued will range from zero to 1,050. No PSUs will vest if the three-year compound annual TSR is below 15%. This award was granted outside of Amended and Restated 2002 Long-Term Incentive and Stock Award Plan and the 2019 Equity Inducement Award Program.

The number of PSUs expected to be earned, based upon the achievement of the TSR market condition, is factored into the grant date Monte Carlo valuation. Compensation expense is recognized on a straight-line basis over the three-year service period, regardless of the eventual number of PSUs that are earned based upon the market condition, provided Mr. Schiller remains an employee at the end of the three-year period. Compensation expense is reversed if at any time during the three-year service period Mr. Schiller is no longer an employee, subject to certain termination and change in control eligibility provisions. These PSUs are subject to a holding period of one year after the vesting date. As such, an illiquidity discount was applied to the grant date fair value. The total grant date fair value of the award was estimated to be $7,571, or $7.21 per share.

Total compensation cost related to this award recognized in the three and nine months ended March 31, 2019 was $621 and $1,008, respectively.

The Company also issued 79 three-year time-based restricted share units to Mr. Schiller.

Investments	9 Months Ended
Investments	Mar. 31, 2019
Equity Method Investments and Joint Ventures [Abstract]
Investments	INVESTMENTS Equity method investment On October 27, 2015, the Company acquired a 14.9% interest in Chop’t Creative Salad Company LLC (“Chop’t”). Chop’tdevelops and operates fast-casual, fresh salad restaurants in the Northeast and Mid-Atlantic United States. Chop’t markets and sells certain of the Company’s branded products and provides consumer insight and feedback. The investment is being accounted for as an equity method investment due to the Company’s representation on the Board of Directors of Chop’t. During fiscal 2018, the Company’s ownership interest was reduced to 13.4% due to the distribution of additional ownership interests. Further ownership interest distributions could potentially dilute the Company’s ownership interest to as low as 11.9%. At March 31, 2019 and June 30, 2018, the carrying value of the Company’s investment in Chop’t was $14,622 and $15,524, respectively, and is included in the Consolidated Balance Sheets as a component of “Investments and joint ventures.”

Financial Instruments Measured At Fair Value

9 Months Ended

Mar. 31, 2019

Fair Value Disclosures [Abstract]

Financial Instruments Measured At Fair Value

FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE

The Company’s financial assets and liabilities measured at fair value are required to be grouped in one of three levels. The levels prioritize the inputs used to measure the fair value of the assets or liabilities. These levels are:


•	Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;


•	Level 2 – Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and


•	Level 3 – Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

The following table presents by level within the fair value hierarchy assets and liabilities measured at fair value on a recurring basis as of March 31, 2019:



	Total		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets:
Rabbi trust investments	$	34,452	$	34,452	$	—	$	—
Forward foreign currency contracts	40		—		40		—
Equity investment	661		661		—		—
Contingent consideration, current	1,735		—		—		1,735
Total	$	36,888	$	35,113	$	40	$	1,735
Liabilities:
Forward foreign currency contracts	$	702	$	—	$	702	$	—
Contingent consideration, non-current	—		—		—		—
Total	$	702	$	—	$	702	$	—

The following table presents by level within the fair value hierarchy assets and liabilities measured at fair value on a recurring basis as of June 30, 2018:



	Total		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets:
Cash equivalents	$	99	$	99	$	—	$	—
Forward foreign currency contracts	365		—		365		—
Equity investments	692		692		—		—
Total	$	1,156	$	791	$	365	$	—
Liabilities:
Forward foreign currency contracts	$	27	$	—	$	27	$	—
Contingent consideration, non-current	1,909		—		—		1,909
Total	$	1,936	$	—	$	27	$	1,909

The rabbi trust investments consist of cash and mutual funds whose fair value is based on quoted prices in active markets for identical assets, and are designated as Level 1 within the valuation hierarchy. The equity investment consists of the Company’s less than 1% investment in Yeo Hiap Seng Limited, a food and beverage manufacturer and distributor based in Singapore. Fair value is measured using the market approach based on quoted prices. The Company utilizes the income approach to measure fair value for its foreign currency forward contracts. The income approach uses pricing models that rely on market observable inputs such as yield curves, currency exchange rates and forward prices.

The Company estimates the original fair value of the contingent consideration as the present value of the expected contingent payments, determined using the weighted probabilities of the possible payments. The Company reassesses the fair value of contingent payments on a periodic basis. Although the Company believes its estimates and assumptions are reasonable, different assumptions, including those regarding the operating results of the respective businesses, or changes in the future may result in different estimated amounts.

The following table summarizes the Level 3 activity for the nine months ended March 31, 2019:



Balance as of June 30, 2018	$	1,909
Contingent consideration adjustment ^(a)	(147		)
Translation adjustment	(27		)
Balance as of March 31, 2019	$	1,735

(a) The change in the fair value of contingent consideration is included in “Project Terra costs and other” in the Company’s Consolidated Statements of Operations.

There were no transfers of financial instruments between the three levels of fair value hierarchy during the nine months ended March 31, 2019 and March 31, 2018.

The carrying amount of cash and cash equivalents, accounts receivable, net, accounts payable and certain accrued expenses and other current liabilities approximate fair value due to the short-term maturities of these financial instruments. The Company’s debt approximates fair value due to the debt bearing fluctuating market interest rates (See Note 10, Debt and Borrowings).

In addition to the instruments named above, the Company also makes fair value measurements in connection with its interim and annual goodwill and trade name impairment testing. These measurements fall into Level 3 of the fair value hierarchy (See Note 9, Goodwill and Other Intangible Assets).

Derivative Instruments

The Company primarily has exposure to changes in foreign currency exchange rates relating to certain anticipated cash flows and firm commitments from its international operations. The Company may enter into certain derivative financial instruments, when available on a cost-effective basis, to manage such risk. Derivative financial instruments are not used for speculative purposes. The fair value of these derivatives is included in prepaid expenses and other current assets and accrued expenses and other current liabilities in the Consolidated Balance Sheet. For derivative instruments that qualify as hedges of probable forecasted cash flows, the effective portion of changes in fair value is temporarily reported in accumulated other comprehensive income and recognized in earnings when the hedged item affects earnings. Fair value hedges and derivative instruments not designated as hedges are marked-to-market each reporting period with any unrealized gains or losses recognized in earnings.

Derivative instruments designated at inception as hedges are measured for effectiveness at the inception of the hedge and on a quarterly basis. These assessments determine whether derivatives designated as qualifying hedges continue to be highly effective in offsetting changes in the cash flows of hedged items. Any ineffective portion of change in fair value is not deferred in accumulated other comprehensive (loss) income and is included in current period results. The Company will discontinue cash flow hedge accounting when the forecasted transaction is no longer probable of occurring on the originally forecasted date or when the hedge is no longer effective. There were no discontinued foreign exchange hedges for the three and nine months ended March 31, 2019 and March 31, 2018.

The notional and fair value amounts of cash flow hedges at March 31, 2019 were $3,920 and $52 of net liabilities, respectively. There were no cash flow hedges or fair value hedges outstanding as of June 30, 2018.

The notional amounts of foreign currency exchange contracts not designated as hedges at March 31, 2019 and June 30, 2018 were $54,884 and $20,986, respectively. The fair values of foreign currency exchange contracts not designated as hedges at March 31, 2019 and June 30, 2018 were $610 of net liabilities and $338 of net assets, respectively.

Gains and losses related to both designated and non-designated foreign currency exchange contracts are recorded in the Company’s Consolidated Statements of Operations based upon the nature of the underlying hedged transaction and were not material for the three and nine months ended March 31, 2019 and March 31, 2018.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Commitments And Contingencies	9 Months Ended
Commitments And Contingencies	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	COMMITMENTS AND CONTINGENCIES Securities Class Actions Filed in Federal Court On August 17, 2016, three securities class action complaints were filed in the Eastern District of New York against the Company alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The three complaints are: (1) Flora v. The Hain Celestial Group, Inc., et al. (the “Flora Complaint”); (2) Lynn v. The Hain Celestial Group, Inc., et al. (the “Lynn Complaint”); and (3) Spadola v. The Hain Celestial Group, Inc., et al. (the “Spadola Complaint” and, together with the Flora and Lynn Complaints, the “Securities Complaints”). On June 5, 2017, the court issued an order for consolidation, appointment of Co-Lead Plaintiffs and approval of selection of co-lead counsel. Pursuant to this order, the Securities Complaints were consolidated under the caption In re The Hain Celestial Group, Inc. Securities Litigation (the “Consolidated Securities Action”), and Rosewood Funeral Home and Salamon Gimpel were appointed as Co-Lead Plaintiffs. On June 21, 2017, the Company received notice that plaintiff Spadola voluntarily dismissed his claims without prejudice to his ability to participate in the Consolidated Securities Action as an absent class member. The Co-Lead Plaintiffs in the Consolidated Securities Action filed a Consolidated Amended Complaint on August 4, 2017 and a Corrected Consolidated Amended Complaint on September 7, 2017 on behalf of a purported class consisting of all persons who purchased or otherwise acquired Hain Celestial securities between November 5, 2013 and February 10, 2017 (the “Amended Complaint”). The Amended Complaint names as defendants the Company and certain of its current and former officers (collectively, the “Defendants”) and asserts violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 based on allegedly materially false or misleading statements and omissions in public statements, press releases and SEC filings regarding the Company’s business, prospects, financial results and internal controls. Defendants filed a motion to dismiss on October 3, 2017. Co-Lead Plaintiffs filed an opposition on December 1, 2017, and Defendants filed the reply on January 16, 2018. On April 4, 2018, the Court requested additional briefing relating to certain aspects of Defendants’ motion to dismiss. In accordance with this request, Lead Plaintiffs submitted their supplemental brief on April 18, 2018, and Defendants submitted an opposition on May 2, 2018. Lead Plaintiffs filed a reply brief on May 9, 2018, and Defendants submitted a sur-reply on May 16, 2018. On March 29, 2019, the Court granted Defendant’s motion, dismissing the Amended Complaint in its entirety, without prejudice to replead. Lead Plaintiffs filed a seconded amended complaint on May 6, 2019. Stockholder Derivative Complaints Filed in State Court On September 16, 2016, a stockholder derivative complaint, Paperny v. Heyer, et al. (the “Paperny Complaint”), was filed in New York State Supreme Court in Nassau County against the Board of Directors and certain officers of the Company alleging breach of fiduciary duty, unjust enrichment, lack of oversight and corporate waste. On December 2, 2016 and December 29, 2016, two additional stockholder derivative complaints were filed in New York State Supreme Court in Nassau County against the Board of Directors and certain officers under the captions Scarola v. Simon (the “Scarola Complaint”) and Shakir v. Simon (the “Shakir Complaint” and, together with the Paperny Complaint and the Scarola Complaint, the “Derivative Complaints”), respectively. Both the Scarola Complaint and the Shakir Complaint allege breach of fiduciary duty, lack of oversight and unjust enrichment. On February 16, 2017, the parties for the Derivative Complaints entered into a stipulation consolidating the matters under the caption In re The Hain Celestial Group (the “Consolidated Derivative Action”) in New York State Supreme Court in Nassau County, ordering the Shakir Complaint as the operative complaint. On November 2, 2017, the parties agreed to stay the Consolidated Derivative Action until April 11, 2018. On April 6, 2018, the parties filed a proposed stipulation agreeing to stay the Consolidated Derivative Action until October 4, 2018, which the Court granted on May 3, 2018. On October 9, 2018, the Court further stayed this matter until December 4, 2018 and on December 4, 2018 further stayed the matter until January 14, 2019. On January 14, 2019, the Court held a status conference and granted Plaintiffs leave to file an amended complaint by March 7, 2019, while continuing the stay as to all other aspects of the case. On March 7, 2019, Plaintiffs filed an amended complaint. The Court held a status conference on March 13, 2019 and continued the stay until a subsequent conference scheduled for May 6, 2019. At the May 6 conference, the Court indicated that the stay will be lifted, and after a preliminary conference for June 13, 2019, a scheduling order will be entered and the case will proceed. Additional Stockholder Class Action and Derivative Complaints Filed in Federal Court On April 19, 2017 and April 26, 2017, two class action and stockholder derivative complaints were filed in the Eastern District of New York against the Board of Directors and certain officers of the Company under the captions Silva v. Simon, et al. (the “Silva Complaint”) and Barnes v. Simon, et al. (the “Barnes Complaint”), respectively. Both the Silva Complaint and the Barnes Complaint allege violation of securities law, breach of fiduciary duty, waste of corporate assets and unjust enrichment. On May 23, 2017, an additional stockholder filed a complaint under seal in the Eastern District of New York against the Board of Directors and certain officers of the Company. The complaint alleges that the Company’s directors and certain officers made materially false and misleading statements in press releases and SEC filings regarding the Company’s business, prospects and financial results. The complaint also alleges that the Company violated its by-laws and Delaware law by failing to hold its 2016 Annual Stockholders Meeting and includes claims for breach of fiduciary duty, unjust enrichment and corporate waste. On August 9, 2017, the Court granted an order to unseal this case and reveal Gary Merenstein as the plaintiff (the “Merenstein Complaint”). On August 10, 2017, the court granted the parties stipulation to consolidate the Barnes Complaint, the Silva Complaint and the Merenstein Complaint under the caption In re The Hain Celestial Group, Inc. Stockholder Class and Derivative Litigation (the “Consolidated Stockholder Class and Derivative Action”) and to appoint Robbins Arroyo LLP and Scott+Scott as Co-Lead Counsel, with the Law Offices of Thomas G. Amon as Liaison Counsel for Plaintiffs. On September 14, 2017, a related complaint was filed under the caption Oliver v. Berke, et al. (the “Oliver Complaint”), and on October 6, 2017, the Oliver Complaint was consolidated with the Consolidated Stockholder Class and Derivative Action. The Plaintiffs filed their consolidated amended complaint under seal on October 26, 2017. On December 20, 2017, the parties agreed to stay Defendants’ time to answer, move, or otherwise respond to the consolidated amended complaint through and including 30 days after a decision is rendered on the motion to dismiss the Amended Complaint in the consolidated Securities Class Actions, described above. After the Court dismissed the Amended Complaint in the Securities Class Actions, the parties to the Consolidated Stockholder Class and Derivative Action agreed to continue the stay of Defendants’ time to answer, move, or otherwise respond to the consolidated amended complaint. The stay is continued through the later of: (a) thirty (30) days after the deadline for plaintiffs to file a second amended complaint in the Securities Class Actions; or, (b) if plaintiffs file a second amended complaint, and Defendants file a motion to dismiss the second amended complaint, thirty (30) days after the Court rules on the motion to dismiss the second amended complaint in the Securities Class Actions. Other In addition to the litigation described above, the Company is and may be a defendant in lawsuits from time to time in the normal course of business. While the results of litigation and claims cannot be predicted with certainty, the Company believes the reasonably possible losses of such matters, individually and in the aggregate, are not material. Additionally, the Company believes the probable final outcome of such matters will not have a material adverse effect on the Company’s consolidated results of operations, financial position, cash flows or liquidity.

Segment Information

9 Months Ended

Mar. 31, 2019

Segment Reporting [Abstract]

Segment Information

SEGMENT INFORMATION

Beginning in the third quarter of fiscal 2018, the Hain Pure Protein operations were classified as discontinued operations as discussed in “Note 5, Discontinued Operations.” Therefore, segment information presented excludes the results of Hain Pure Protein. As a result, the Company is now managed in seven operating segments: the United States, United Kingdom, Tilda, Ella’s Kitchen UK, Europe, Canada and Hain Ventures (formerly known as Cultivate).

The prior period segment information contained below has been adjusted to reflect the Company’s revised operating and reporting structure.

Net sales and operating income are the primary measures used by the Company’s Chief Operating Decision Maker (“CODM”) to evaluate segment operating performance and to decide how to allocate resources to segments. The CODM is the Company’s Chief Executive Officer. Expenses related to certain centralized administration functions that are not specifically related to an operating segment are included in Corporate and Other. Corporate and Other expenses are comprised mainly of the compensation and related expenses of certain of the Company’s senior executive officers and other selected employees who perform duties related to the entire enterprise, as well as expenses for certain professional fees, facilities and other items which benefit the Company as a whole. Additionally, certain Project Terra costs are included in “Corporate and Other.” Expenses that are managed centrally, but can be attributed to a segment, such as employee benefits and certain facility costs, are allocated based on reasonable allocation methods. Assets are reviewed by the CODM on a consolidated basis and therefore are not reported by operating segment.

The following tables set forth financial information about each of the Company’s reportable segments. Transactions between reportable segments were insignificant for all periods presented.



	Three Months Ended March 31,						Nine Months Ended March 31,
	2019			2018			2019			2018
Net Sales:
United States	$	266,445		$	281,052		$	769,585		$	815,013
United Kingdom	227,206			238,321			671,121			698,968
Rest of World	106,146			113,347			304,080			324,190
	$	599,797		$	632,720		$	1,744,786		$	1,838,171

Operating Income/(Loss):
United States	$	17,099		$	24,974		$	26,449		$	67,696
United Kingdom	18,147			13,863			36,822			37,062
Rest of World	10,868			11,059			27,078			30,591
	$	46,114		$	49,896		$	90,349		$	135,349
Corporate and Other ^(a)	(22,249		)	(20,642		)	(105,975		)	(45,889		)
	$	23,865		$	29,254		$	(15,626	)	$	89,460

(a) For the three months ended March 31, 2019, Corporate and Other includes $455 of Chief Executive Officer Succession Plan expense, net and $7,562 of Project Terra costs and other. For the three months ended March 31, 2018, Corporate and Other includes $4,175 of Project Terra costs and other $3,313 of accounting review and remediation costs.

For the nine months ended March 31, 2019, Corporate and Other includes $30,156 of Chief Executive Officer Succession Plan expense, net, $21,045 of Project Terra costs and other and $4,334 of accounting review and remediation costs. Corporate and Other for the nine months ended March 31, 2019 also includes impairment charges of $17,900 ($11,300 related to the United States segment, $2,787 related to the United Kingdom segment and $3,813 in Rest of World) related to certain of the Company’s tradenames. For the nine months ended March 31, 2018, Corporate and Other included $7,429 of Project Terra costs and other and net expense of $6,406 of accounting review and remediation costs, net of insurance proceeds, consisting of $11,406 of costs incurred in the nine months ended March 31, 2018 offset by insurance proceeds of $5,000.

The Company’s long-lived assets, which primarily represent net property, plant and equipment, by geographic area were as follows:



	March 31, 2019		June 30, 2018
United States	$	115,243	$	99,650
United Kingdom	179,226		174,214
All Other	86,331		86,700
Total	$	380,800	$	360,564

The Company’s net sales by geographic region, which are generally based on the location of the Company’s subsidiary, were as follows:



	Three Months Ended March 31,				Nine Months Ended March 31,
	2019		2018		2019		2018
United States	$	279,609	$	296,635	$	807,899	$	860,987
United Kingdom	227,206		238,321		671,121		698,968
All Other	92,982		97,764		265,766		278,216
Total	$	599,797	$	632,720	$	1,744,786	$	1,838,171

Basis Of Presentation (Policies)	9 Months Ended
Basis Of Presentation (Policies)	Mar. 31, 2019
Accounting Policies [Abstract]
Newly Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Effective	Newly Adopted Accounting Pronouncements ASU 2014-09, Revenue from Contracts with Customers (Topic 606) In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). This guidance outlines a single, comprehensive model for accounting for revenue from contracts with customers, providing a single five-step model to be applied to all revenue transactions. The guidance also requires improved disclosures to assist users of the financial statements to better understand the nature, amount, timing and uncertainty of revenue that is recognized. Subsequent to the issuance of ASU 2014-09, the FASB issued various additional ASUs clarifying and amending this new revenue guidance. The Company adopted the new revenue standard on July 1, 2018 using the modified retrospective transition method. The adoption did not materially impact our results of operations or financial position, and, as a result, comparisons of revenues and operating profit between periods were not materially affected by the adoption of ASU 2014-09. The Company recorded a net increase to beginning retained earnings of $163 on July 1, 2018 due to the cumulative impact of adopting ASU 2014-09. Additionally, as our products exhibit similar economic characteristics, are sold through similar channels to similar customers and are recognized at a point in time, we have concluded that the Company’s segment disclosures in Note 17, Segment Information, are indicative of the level of revenue disaggregation required under ASU 2014-09. ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10) In January 2016, the FASB issued ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 requires that most equity investments be measured at fair value, with subsequent changes in fair value recognized in net income. The pronouncement also impacts financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. We adopted ASU 2016‑01 in the three months ended September 30, 2018, which resulted in a net decrease to beginning retained earnings of $348 on July 1, 2018, representing the accumulated unrealized losses (net of tax) reported in accumulated other comprehensive income (loss) for available-for-sale equity securities on June 30, 2018. We no longer classify equity investments as trading or available-for-sale and will no longer recognize unrealized holding gains and losses on equity securities previously classified as available-for-sale in other comprehensive income (loss) as a result of adoption of ASU 2016-01. Recently Issued Accounting Pronouncements Not Yet Effective In February 2016, the FASB issued ASU 2016-02, Leases (ASC 842). The amendments in this ASU replace most of the existing U.S. GAAP lease accounting guidance in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The ASU is effective for annual periods beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. The ASU requires lessees and lessors to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB approved amendments to create an optional transition method that will provide an option to use the effective date of ASC 842 as the date of initial application of the transition. Under the new transition method, a reporting entity would initially apply the new lease requirements at the effective date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption, continue to report comparative periods presented in the financial statements in the period of adoption in accordance with current U.S. GAAP (i.e., ASC 840, Leases) and provide the required disclosures under ASC 840 for all periods presented under current U.S. GAAP. We will adopt the standard effective July 1, 2019. As part of the Company’s assessment work to-date, the Company has formed an implementation work team to perform a comprehensive evaluation of the impact of the adoption of this guidance, which includes assessing the Company’s lease portfolio, the impact to business processes and internal controls over financial reporting and the related disclosure requirements. Additionally, the Company is implementing lease accounting software to assist in the quantification of the expected impact on the Consolidated Balance Sheet and to facilitate the calculations of the related accounting entries and disclosures, as well as to facilitate accounting, presentation and disclosure for all leases after the initial date of application under the new standard. While the Company is continuing to assess all potential impacts of the standard, the most significant impact relates to the recognition of new right-of-use assets and lease liabilities on the balance sheet for manufacturing, warehouse and office space operating leases. We believe that all of these leases will continue to be classified as operating leases under the new standard. We expect the accounting for capital leases to remain substantially unchanged. Refer to Note 2, Summary of Significant Accounting Policies and Practices, in the Notes to the Consolidated Financial Statements as of June 30, 2018 and for the fiscal year then ended included in the Form 10-K for a detailed discussion on additional recently issued accounting pronouncements not yet adopted by the Company. There has been no change to the statements made in the Form 10-K as of the date of filing of this Form 10-Q.

Earnings (Loss) Per Share (Tables)

9 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Computation Of Basic And Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted net (loss) income per share:



	Three Months Ended March 31,						Nine Months Ended March 31,
	2019			2018			2019			2018
Numerator:
Net income (loss) from continuing operations	$	10,088		$	25,241		$	(42,291	)	$	86,984
Net loss from discontinued operations, net of tax	(75,925		)	(12,555		)	(127,472		)	(7,349		)
Net (loss) income	$	(65,837	)	$	12,686		$	(169,763	)	$	79,635

Denominator:
Basic weighted average shares outstanding	104,117			103,918			104,045			103,821
Effect of dilutive stock options, unvested restricted stock and unvested restricted share units	217			585			—			652
Diluted weighted average shares outstanding	104,334			104,503			104,045			104,473

Basic net (loss) income per common share:
Continuing operations	$	0.10		$	0.24		$	(0.41	)	$	0.84
Discontinued operations	(0.73		)	(0.12		)	(1.23		)	(0.07		)
Basic net (loss) income per common share	$	(0.63	)	$	0.12		$	(1.63	)	$	0.77

Diluted net (loss) income per common share:
Continuing operations	$	0.10		$	0.24		$	(0.41	)	$	0.83
Discontinued operations	(0.73		)	(0.12		)	(1.23		)	(0.07		)
Diluted net (loss) income per common share	$	(0.63	)	$	0.12		$	(1.63	)	$	0.76

Discontinued Operations (Tables)

9 Months Ended

Mar. 31, 2019

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations



	Three Months Ended March 31,						Nine Months Ended March 31,
	2019			2018			2019			2018
Net sales	$	88,729		$	118,198		$	349,449		$	396,227
Cost of sales	88,277			113,629			356,073			373,122
Gross profit (loss)	452			4,569			(6,624		)	23,105
Selling, general and administrative expense	4,039			5,888			13,031			14,458
Asset impairments ⁽¹⁾	51,348			—			109,252			—
Other expense	2,182			805			7,377			3,258
Loss on sale of discontinued operations	40,223			—			40,223			—
Net (loss) income from discontinued operations before income taxes	(97,340		)	(2,124		)	(176,507		)	5,389
(Benefit) provision for income taxes	(21,415		)	10,431			(49,035		)	12,738
Net loss from discontinued operations, net of tax	$	(75,925	)	$	(12,555	)	$	(127,472	)	$	(7,349	)

Assets and liabilities of discontinued operations presented in the Consolidated Balance Sheets as of March 31, 2019 and June 30, 2018 are included in the following table:



	March 31,			June 30,
ASSETS	2019			2018
Cash and cash equivalents	$	3,678		$	6,461
Accounts receivable, less allowance for doubtful accounts	11,680			21,616
Inventories	31,600			105,359
Prepaid expenses and other current assets	1,906			5,604
Property, plant and equipment, net	49,537			83,776
Goodwill	41,089			41,089
Trademarks and other intangible assets, net	33,762			51,029
Other assets	2,636			4,381
Deferred tax assets ⁽²⁾	37,925			—
Impairments of long-lived assets held for sale⁽¹⁾	(77,632		)	(78,464		)
Current assets of discontinued operations⁽³⁾	$	136,181		$	240,851

LIABILITIES
Accounts payable	$	11,211		$	31,762
Accrued expenses and other current liabilities	3,914			6,880
Deferred tax liabilities ⁽²⁾	—			11,111
Other noncurrent liabilities	70			93
Current liabilities of discontinued operations⁽³⁾	$	15,195		$	49,846

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Inventories (Tables)

9 Months Ended

Mar. 31, 2019

Inventory Disclosure [Abstract]

Components Of Inventories

Inventories consisted of the following:



	March 31, 2019		June 30, 2018
Finished goods	$	235,232	$	231,926
Raw materials, work-in-progress and packaging	160,014		159,599
	$	395,246	$	391,525

Property, Plant And Equipment, Net (Tables)

9 Months Ended

Mar. 31, 2019

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment, Net

Property, plant and equipment, net consisted of the following:



	March 31, 2019		June 30, 2018
Land	$	28,049	$	28,378
Buildings and improvements	95,604		83,289
Machinery and equipment	315,574		323,348
Computer hardware and software	56,168		54,092
Furniture and fixtures	18,624		17,894
Leasehold improvements	31,269		31,519
Construction in progress	30,556		17,280
	575,844		555,800
Less: Accumulated depreciation and amortization	244,774		245,628
	$	331,070	$	310,172

Goodwill And Other Intangible Assets (Tables)

9 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Changes In Carrying Amount Of Goodwill

The following table shows the changes in the carrying amount of goodwill by business segment:



	United States		United Kingdom			Rest of World			Total
Balance as of June 30, 2018 ^(a)	$	552,814	$	377,163		$	94,159		$	1,024,136
Translation and other adjustments, net	—		(5,203		)	(2,070		)	(7,273		)
Balance as of March 31, 2019^(a)	$	552,814	$	371,960		$	92,089		$	1,016,863

Components Of Trademarks And Other Intangible Assets

The following table sets forth Consolidated Balance Sheet information for intangible assets, excluding goodwill, subject to amortization and intangible assets not subject to amortization:



	March 31, 2019			June 30, 2018
Non-amortized intangible assets:
Trademarks and tradenames ^(a)	$	364,068		$	385,609
Amortized intangible assets:
Other intangibles	236,333			239,323
Less: accumulated amortization	(124,819		)	(114,545		)
Net carrying amount	$	475,582		$	510,387

(a) The gross carrying value of trademarks and tradenames is reflected net of $83,734 and $65,834 of accumulated impairment charges at March 31, 2019 and at June 30, 2018, respectively.

Finite-lived Intangible Assets Amortization Expense

Amortization expense included in continuing operations was as follows:



	Three Months Ended March 31,				Nine Months Ended March 31,
	2019		2018		2019		2018
Amortization of acquired intangibles	$	3,802	$	4,713	$	11,567	$	13,859

Debt And Borrowings (Tables)

9 Months Ended

Mar. 31, 2019

Debt Disclosure [Abstract]

Schedule Of Debt And Borrowings

Debt and borrowings consisted of the following:



	March 31, 2019			June 30, 2018
Revolving credit facility	$	455,206		$	401,852
Term loan	285,000			296,250
Less: Unamortized issuance costs	(579		)	(692		)
Tilda short-term borrowing arrangements	6,654			9,338
Other borrowings	5,442			7,358
	751,723			714,106
Short-term borrowings and current portion of long-term debt	22,522			26,605
Long-term debt, less current portion	$	729,201		$	687,501

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Accumulated Other Comprehensive Income (Loss) (Tables)

9 Months Ended

Mar. 31, 2019

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The following table presents the changes in accumulated other comprehensive income (loss):



	Three Months Ended March 31,						Nine Months Ended March 31,
	2019			2018			2019			2018
Foreign currency translation adjustments:
Other comprehensive income (loss) before reclassifications ⁽¹⁾	$	20,934		$	37,868		$	(20,533	)	$	80,065
Deferred (losses)/gains on cash flow hedging instruments:
Other comprehensive (loss) income before reclassifications	(42		)	—			(42		)	39
Amounts reclassified into income ⁽²⁾	—			—			—			(106		)
Unrealized gains/(losses) on equity investment:
Other comprehensive loss before reclassifications	—			(101		)	—			(103		)
Net change in accumulated other comprehensive income (loss)	$	20,892		$	37,767		$	(20,575	)	$	79,895

Stock-Based Compensation And Incentive Performance Plans (Tables)

9 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Compensation Cost And Related Income Tax Benefits Recognized

Compensation cost and related income tax benefits recognized in the Consolidated Statements of Operations for stock-based compensation plans were as follows:



	Three Months Ended March 31,				Nine Months Ended March 31,
	2019		2018		2019		2018
Selling, general and administrative expense	$	3,937	$	2,936	$	5,502	$	10,258
Chief Executive Officer Succession Plan expense, net	—		—		429		—
Discontinued operations	6		—		58		—
Total compensation cost recognized for stock-based compensation plans	$	3,943	$	2,936	$	5,989	$	10,258
Related income tax benefit	$	470	$	971	$	765	$	3,391

Non-Vested Restricted Stock And Restricted Share Unit Awards

A summary of the restricted stock and restricted share unit activity for the nine months ended March 31, 2019 is as follows:



	Number of Shares and Units		Weighted Average Grant Date Fair Value (per share)
Non-vested restricted stock, restricted share units, and performance units at June 30, 2018	1,057		$	22.29
Granted	3,470		$	7.13
Vested	(291	)	$	26.50
Forfeited	(333	)	$	17.68
Non-vested restricted stock, restricted share units, and performance units at March 31, 2019	3,903		$	8.89

Restricted Stock Grant Information



	Nine Months Ended March 31,
	2019		2018
Fair value of restricted stock and restricted share units granted	$	24,734	$	14,595
Fair value of shares vested	$	7,725	$	14,622
Tax benefit recognized from restricted shares vesting	$	3,331	$	4,970

Summary Of Stock Option Activity

A summary of the stock option activity for the nine months ended March 31, 2019 is as follows:



	Number of Options	Weighted Average Exercise Price		Weighted Average Contractual Life (years)	Aggregate Intrinsic Value
Options outstanding and exercisable at June 30, 2018	122	$	2.26
Exercised	—	—
Options outstanding and exercisable at March 31, 2019	122	$	2.26	12.3	$	2,544

2019 Equity Inducement Award Program

As such, an illiquidity discount was applied to the grant date fair value.



Grant Date	Shares Issued	Fair Value Per Share		Grant Date Fair Value
February 19, 2019	739	$	1.79	$	1,324
March 29, 2019	187	$	3.01	563
Total	926			$	1,887

Financial Instruments Measured At Fair Value (Tables)

9 Months Ended

Mar. 31, 2019

Fair Value Disclosures [Abstract]

Assets And Liabilities Measured At Fair Value On A Recurring Basis

The following table presents by level within the fair value hierarchy assets and liabilities measured at fair value on a recurring basis as of March 31, 2019:



	Total		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets:
Rabbi trust investments	$	34,452	$	34,452	$	—	$	—
Forward foreign currency contracts	40		—		40		—
Equity investment	661		661		—		—
Contingent consideration, current	1,735		—		—		1,735
Total	$	36,888	$	35,113	$	40	$	1,735
Liabilities:
Forward foreign currency contracts	$	702	$	—	$	702	$	—
Contingent consideration, non-current	—		—		—		—
Total	$	702	$	—	$	702	$	—

The following table presents by level within the fair value hierarchy assets and liabilities measured at fair value on a recurring basis as of June 30, 2018:



	Total		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets:
Cash equivalents	$	99	$	99	$	—	$	—
Forward foreign currency contracts	365		—		365		—
Equity investments	692		692		—		—
Total	$	1,156	$	791	$	365	$	—
Liabilities:
Forward foreign currency contracts	$	27	$	—	$	27	$	—
Contingent consideration, non-current	1,909		—		—		1,909
Total	$	1,936	$	—	$	27	$	1,909

Level 3 Activity

The following table summarizes the Level 3 activity for the nine months ended March 31, 2019:



Balance as of June 30, 2018	$	1,909
Contingent consideration adjustment ^(a)	(147		)
Translation adjustment	(27		)
Balance as of March 31, 2019	$	1,735

(a) The change in the fair value of contingent consideration is included in “Project Terra costs and other” in the Company’s Consolidated Statements of Operations.

Segment Information (Tables)

9 Months Ended

Mar. 31, 2019

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

The following tables set forth financial information about each of the Company’s reportable segments. Transactions between reportable segments were insignificant for all periods presented.



	Three Months Ended March 31,						Nine Months Ended March 31,
	2019			2018			2019			2018
Net Sales:
United States	$	266,445		$	281,052		$	769,585		$	815,013
United Kingdom	227,206			238,321			671,121			698,968
Rest of World	106,146			113,347			304,080			324,190
	$	599,797		$	632,720		$	1,744,786		$	1,838,171

Operating Income/(Loss):
United States	$	17,099		$	24,974		$	26,449		$	67,696
United Kingdom	18,147			13,863			36,822			37,062
Rest of World	10,868			11,059			27,078			30,591
	$	46,114		$	49,896		$	90,349		$	135,349
Corporate and Other ^(a)	(22,249		)	(20,642		)	(105,975		)	(45,889		)
	$	23,865		$	29,254		$	(15,626	)	$	89,460

Schedule of Long-lived Assets

The Company’s long-lived assets, which primarily represent net property, plant and equipment, by geographic area were as follows:



	March 31, 2019		June 30, 2018
United States	$	115,243	$	99,650
United Kingdom	179,226		174,214
All Other	86,331		86,700
Total	$	380,800	$	360,564

Net Sales Geographic Area

The Company’s net sales by geographic region, which are generally based on the location of the Company’s subsidiary, were as follows:



	Three Months Ended March 31,				Nine Months Ended March 31,
	2019		2018		2019		2018
United States	$	279,609	$	296,635	$	807,899	$	860,987
United Kingdom	227,206		238,321		671,121		698,968
All Other	92,982		97,764		265,766		278,216
Total	$	599,797	$	632,720	$	1,744,786	$	1,838,171

Business (Details)	Mar. 31, 2019 country
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of countries in which entity operates (more than)	80

Basis Of Presentation (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jul. 01, 2018	Jun. 30, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase (decrease) in retained earnings	$ 708,568		$ 878,516
ASU 2014-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase (decrease) in retained earnings		$ 163
ASU 2016-01 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase (decrease) in retained earnings		$ (348)

Chief Executive Officer Succession Plan (Details) - USD ($) $ in Thousands		3 Months Ended	4 Months Ended	9 Months Ended
	Nov. 05, 2018	Mar. 31, 2019	Nov. 04, 2018	Mar. 31, 2019
CEO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cash separation payment			$ 34,295	$ 33,051
Continuation costs			$ 208
Former CEO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Consulting fees	$ 975
Former CEO [Member] \| Chief Executive Officer Succession Plan expense, net
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Consulting fees		$ 325

Earnings (Loss) Per Share (Computation Of Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Mar. 31, 2019	Mar. 31, 2018
Earnings Per Share [Abstract]
Net income (loss) from continuing operations	$ 10,088			$ 25,241			$ (42,291)	$ 86,984
Net loss from discontinued operations, net of tax	(75,925)			(12,555)			(127,472)	(7,349)
Net (loss) income	$ (65,837)	$ (66,501)	$ (37,425)	$ 12,686	$ 47,103	$ 19,846	$ (169,763)	$ 79,635
Denominator:
Basic weighted average shares outstanding (shares)	104,117			103,918			104,045	103,821
Effect of dilutive stock options, unvested restricted stock and unvested restricted share units (shares)	217			585			0	652
Diluted weighted average shares outstanding (shares)	104,334			104,503			104,045	104,473
Basic net (loss) income per common share:
Basic net income (loss) per common share from continuing operations (USD per share)	$ 0.10			$ 0.24			$ (0.41)	$ 0.84
Basic net income (loss) per common share from discontinued operations (USD per share)	(0.73)			(0.12)			(1.23)	(0.07)
Basic net income (loss) per common share (USD per share)	(0.63)			0.12			(1.63)	0.77
Diluted net (loss) income per common share:
Diluted net income (loss) per common share from continuing operations (USD per share)	0.10			0.24			(0.41)	0.83
Diluted net income (loss) per common share from discontinued operations (USD per share)	(0.73)			(0.12)			(1.23)	(0.07)
Diluted net income (loss) per common share (USD per share)	$ (0.63)			$ 0.12			$ (1.63)	$ 0.76

Earnings (Loss) Per Share (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Jun. 21, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Authorized amount					$ 250,000,000
Remaining authorized repurchase amount	$ 250,000,000		$ 250,000,000
Stock Based Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	3,071,000	559,000	3,117,000	559,000
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	273,000		621,000
Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	0	0	110,000	0

Discontinued Operations (Narrative) (Details) - Hain Pure Protein [Member] - Disposed of by Sale [Member] - USD ($) $ in Thousands			3 Months Ended		9 Months Ended
	May 08, 2019	Feb. 15, 2019	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale		$ 25,000
Stand by letter of credit		$ 10,000
Letter of credit, expiration period		19 months
Letter of credit, percent of maximum draw		120.00%
Loss on sale of discontinued operations, pre-tax			$ (40,223)	$ 0	$ (40,223)	$ 0
Loss on sale of discontinued operations, net			$ 29,685
Subsequent Event [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale	$ 80,000

Discontinued Operations (Statements of Operations) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net loss from discontinued operations, net of tax	$ (75,925)	$ (12,555)	$ (127,472)	$ (7,349)
Hain Pure Protein [Member] \| Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales	88,729	118,198	349,449	396,227
Cost of sales	88,277	113,629	356,073	373,122
Gross profit (loss)	452	4,569	(6,624)	23,105
Selling, general and administrative expense	4,039	5,888	13,031	14,458
Asset impairments (1)	51,348	0	109,252	0
Other expense	2,182	805	7,377	3,258
Loss on sale of discontinued operations	40,223	0	40,223	0
Net (loss) income from discontinued operations before income taxes	(97,340)	(2,124)	(176,507)	5,389
(Benefit) provision for income taxes	(21,415)	10,431	(49,035)	12,738
Net loss from discontinued operations, net of tax	$ (75,925)	$ (12,555)	$ (127,472)	$ (7,349)

Discontinued Operations (Balance Sheet) (Details) - Hain Pure Protein [Member] - Disposed of by Sale [Member] - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2019	Jun. 30, 2018
ASSETS
Cash and cash equivalents	$ 3,678	$ 3,678	$ 6,461
Accounts receivable, less allowance for doubtful accounts	11,680	11,680	21,616
Inventories	31,600	31,600	105,359
Prepaid expenses and other current assets	1,906	1,906	5,604
Property, plant and equipment, net	49,537	49,537	83,776
Goodwill	41,089	41,089	41,089
Trademarks and other intangible assets, net	33,762	33,762	51,029
Other assets	2,636	2,636	4,381
Deferred tax assets	37,925	37,925	0
Impairments of long-lived assets held for sale	(77,632)	(77,632)	(78,464)
Current assets of discontinued operations	136,181	136,181	240,851
LIABILITIES
Accounts payable	11,211	11,211	31,762
Accrued expenses and other current liabilities	3,914	3,914	6,880
Deferred tax liabilities	0	0	11,111
Other noncurrent liabilities	70	70	93
Current liabilities of discontinued operations	15,195	15,195	$ 49,846
Asset impairment charges	51,348	$ 109,252
Reversal of deferred tax liability related to book/tax basis difference	$ 12,250

Acquisitions (Details) £ in Thousands, $ in Thousands			3 Months Ended	9 Months Ended
Acquisitions (Details) £ in Thousands, $ in Thousands	Dec. 01, 2017 GBP (£)	Dec. 01, 2017 USD ($)	Mar. 31, 2018 USD ($)	Mar. 31, 2019 USD ($)	Mar. 31, 2018 USD ($)
Business Acquisition [Line Items]
Acquisition related costs			$ 8		$ 336
Cash paid, net of cash acquired				$ 0	$ 13,064
Clarks [Member]
Business Acquisition [Line Items]
Cash paid, net of cash acquired	£ 9,179	$ 12,368
Contingent consideration, high range \| £	£ 1,500
Contingent consideration arrangements, period for achievement operating results	18 months	18 months
Clarks [Member] \| Sales [Member]
Business Acquisition [Line Items]
Concentration risk, percentage, less than	1.00%	1.00%

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Inventory Disclosure [Abstract]
Finished goods	$ 235,232	$ 231,926
Raw materials, work-in-progress and packaging	160,014	159,599
Total inventories	$ 395,246	$ 391,525

Property, Plant And Equipment, Net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 575,844			$ 575,844		$ 555,800
Less: Accumulated depreciation and amortization	244,774			244,774		245,628
Property, plant and equipment, net	331,070			331,070		310,172
Depreciation	8,110	$ 8,212		24,294	$ 24,580
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	28,049			28,049		28,378
Buildings and improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	95,604			95,604		83,289
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	315,574			315,574		323,348
Computer hardware and software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	56,168			56,168		54,092
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	18,624			18,624		17,894
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	31,269			31,269		31,519
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 30,556			$ 30,556		$ 17,280
Manufacturing facility [Member] \| United Kingdom [Member]
Property, Plant and Equipment [Line Items]
Non-cash impairment charge			$ 5,809

Goodwill And Other Intangible Assets (Changes In Carrying Amount Of Goodwill) (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2019	Jun. 30, 2018
Goodwill
Goodwill	$ 1,024,136
Translation and other adjustments, net	(7,273)
Goodwill	1,016,863
Accumulated impairment losses	134,277	$ 134,277
United States [Member]
Goodwill
Goodwill	552,814
Translation and other adjustments, net	0
Goodwill	552,814
United Kingdom [Member]
Goodwill
Goodwill	377,163
Translation and other adjustments, net	(5,203)
Goodwill	371,960
Accumulated impairment losses	97,358	97,358
Rest of World [Member]
Goodwill
Goodwill	94,159
Translation and other adjustments, net	(2,070)
Goodwill	92,089
Europe [Member]
Goodwill
Accumulated impairment losses	29,219	29,219
Cultivate [Member] \| Operating Segments [Member]
Goodwill
Accumulated impairment losses	$ 7,700	$ 7,700

Goodwill And Other Intangible Assets (Components Of Trademarks And Other Intangible Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Indefinite-lived Intangible Assets [Line Items]
Trademarks and tradenames	$ 364,068	$ 385,609
Other intangibles	236,333	239,323
Less: accumulated amortization	(124,819)	(114,545)
Net carrying amount	475,582	510,387
Trademarks and Tradenames [Member]
Indefinite-lived Intangible Assets [Line Items]
Accumulated impairment charge	$ 83,734	$ 65,834

Goodwill And Other Intangible Assets (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2019	Jun. 30, 2018
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives		3 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives		25 years
Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Long-lived asset impairment	$ 17,900		$ 5,632
United States [Member] \| Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Long-lived asset impairment	11,300
United Kingdom [Member] \| Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Long-lived asset impairment	2,787		532
Rest of World [Member] \| Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Long-lived asset impairment	$ 3,813		$ 5,100

Goodwill And Other Intangible Assets (Amortization Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of acquired intangibles	$ 3,802	$ 4,713	$ 11,567	$ 13,859

Debt And Borrowings (Components Of Debt) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Line of Credit Facility [Line Items]
Less: Unamortized issuance costs	$ (579)	$ (692)
Other borrowings	5,442	7,358
Long-term debt	751,723	714,106
Short-term borrowings and current portion of long-term debt	22,522	26,605
Long-term debt, less current portion	729,201	687,501
Credit Agreement [Member] \| Unsecured revolving credit facility [Member]
Line of Credit Facility [Line Items]
Line of credit	455,206	401,852
Term Loan [Member] \| Line of Credit [Member]
Line of Credit Facility [Line Items]
Line of credit	285,000	296,250
Tilda [Member] \| Line of Credit [Member]
Line of Credit Facility [Line Items]
Tilda short-term borrowing arrangements	$ 6,654	$ 9,338

Debt And Borrowings (Credit Agreement) (Details)			3 Months Ended									9 Months Ended
Debt And Borrowings (Credit Agreement) (Details)	Feb. 06, 2018 USD ($)	Dec. 12, 2014	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019 USD ($)	Dec. 31, 2018	Dec. 31, 2019	Mar. 31, 2019 USD ($)	Jun. 30, 2018 USD ($)
Unsecured revolving credit facility [Member] \| Credit Agreement [Member]
Line of Credit Facility [Line Items]
Revolving credit facility	$ 1,000,000,000
Interest coverage ratio		4.00
Leverage ratio		3.50
Consolidated leverage ratio		4.0
Term Loan [Member] \| Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Revolving credit facility	300,000
Additional borrowing capacity	400,000
Consolidated leverage ratio										3.75	4.0
Available borrowing capacity										$ 528,570,000			$ 528,570,000
Weighted average interest rate										4.30%			4.30%
Periodic payment	$ 3,750,000
Term Loan [Member] \| Amended Credit Agreement [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage													0.20%
Term Loan [Member] \| Amended Credit Agreement [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage													0.45%
Term Loan [Member] \| Amended Credit Agreement [Member] \| Forecast [Member]
Line of Credit Facility [Line Items]
Leverage ratio								3.5
Consolidated leverage ratio									3.75
Term Loan [Member] \| Amended Credit Agreement [Member] \| Eurocurrency Rate [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Basis spread on variable rate													0.875%
Term Loan [Member] \| Amended Credit Agreement [Member] \| Eurocurrency Rate [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Basis spread on variable rate													2.50%
Term Loan [Member] \| Amended Credit Agreement [Member] \| Base Rate [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Basis spread on variable rate													0.00%
Term Loan [Member] \| Amended Credit Agreement [Member] \| Base Rate [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Basis spread on variable rate													1.50%
Term Loan [Member] \| May 3rd Amended Credit Agreement [Member] \| Hain Pure Protein [Member]
Line of Credit Facility [Line Items]
Interest coverage ratio										0.25
Term Loan [Member] \| May 3rd Amended Credit Agreement [Member] \| Forecast [Member]
Line of Credit Facility [Line Items]
Interest coverage ratio				4.0	3.75		3.0
Consolidated leverage ratio			4.25			4.0	4.75					5.0
Term Loan [Member] \| Term Loan [Member]
Line of Credit Facility [Line Items]
Line of credit facility outstanding										$ 285,000,000			$ 285,000,000	$ 296,250,000
Letter of credit [Member] \| Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Borrowings outstanding under credit agreement										$ 16,224,000			$ 16,224,000

Debt And Borrowings (Tilda Short-Term Borrowing Arrangements) (Details) - Line of Credit [Member] - Tilda [Member] $ in Thousands	9 Months Ended
	Mar. 31, 2019 GBP (£)	Mar. 31, 2019 USD ($)	Jun. 30, 2018 USD ($)
Short-term Debt [Line Items]
Revolving credit facility \| £	£ 52,000,000
Debt term	6 months
Short-term debt, weighted average interest rate	3.27%	3.27%
Tilda short-term borrowing arrangements \| $		$ 6,654	$ 9,338

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Income Tax [Line Items]
Measurement period adjustment, additional income tax expense related to transition tax			$ 8,205
Effective income tax rate reconciliation	23.20%	(5.50%)	3.90%	(15.30%)
Expiration of statute of limitations				$ 3,754
Hain Pure Protein [Member] \| Disposed of by Sale [Member]
Income Tax [Line Items]
(Benefit) provision for income taxes	$ (21,415)	$ 10,431	$ (49,035)	$ 12,738
Reversal of deferred tax liability related to book/tax basis difference	$ 12,250

- Definition

Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.

+ References + Details

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)	3 Months Ended						9 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Mar. 31, 2019	Mar. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net change in accumulated other comprehensive income (loss)	$ 20,892,000	$ (27,948,000)	$ (13,519,000)	$ 37,767,000	$ 8,341,000	$ 33,787,000	$ (20,575,000)	$ 79,895,000
Foreign currency translation adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive income (loss) before reclassifications	20,934,000			37,868,000			(20,533,000)	80,065,000
Deferred gains/(losses) on cash flow hedging instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive income (loss) before reclassifications	(42,000)			0			(42,000)	39,000
Amounts reclassified into income	0			0			0	(106,000)
Amounts reclassified into income for deferred gains/(losses) on cash flow hedging instruments	0			0			0	132,000
Unrealized gain/(loss) on available for sale investment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive income (loss) before reclassifications	0			(101,000)			0	(103,000)
Intra-entity foreign currency transactions [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive income (loss) before reclassifications	$ (403,000)			$ 670,000			$ (875,000)	$ 1,736,000

Stock-Based Compensation And Incentive Performance Plans (Stock Plans Narrative) (Details)	9 Months Ended
	Mar. 31, 2019 plan
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of plans	2

Stock-Based Compensation And Incentive Performance Plans (Compensation Cost And Related Income Tax Benefits Recognized) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total compensation cost recognized for stock-based compensation plans	$ 3,943	$ 2,936	$ 5,989	$ 10,258
Related income tax benefit	470	971	765	3,391
Selling, general and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Selling, general and administrative expense	3,937	2,936	5,502	10,258
Chief Executive Officer Succession Plan expense, net
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Selling, general and administrative expense	0	0	429	0
Discontinued operations
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Selling, general and administrative expense	$ 6	$ 0	$ 58	$ 0

Stock-Based Compensation And Incentive Performance Plans (Non-Vested Restricted Stock And Restricted Share Unit Awards) (Details) - Restricted Stock [Member] shares in Thousands	9 Months Ended
	Mar. 31, 2019 $ / shares shares
Number of Shares and Units
Non-vested restricted stock, restricted share units, and performance units, beginning balance (shares) \| shares	1,057
Granted (shares) \| shares	3,470
Vested (shares) \| shares	(291)
Forfeited (shares) \| shares	(333)
Non-vested restricted stock, restricted share units, and performance units, ending balance (shares) \| shares	3,903
Weighted Average Grant Date Fair Value (per share)
Non-vested restricted stock, restricted share units, and performance units beginning balance (USD per share) \| $ / shares	$ 22.29
Granted (USD per share) \| $ / shares	7.13
Vested (USD per share) \| $ / shares	26.50
Forfeited (USD per share) \| $ / shares	17.68
Non-vested restricted stock, restricted share units, and performance units ending balance (USD per share) \| $ / shares	$ 8.89

Stock-Based Compensation And Incentive Performance Plans (Restricted Stock Grant Information) (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense	$ 24,083
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of restricted stock and restricted share units granted	24,734	$ 14,595
Fair value of shares vested	7,725	14,622
Tax benefit recognized from restricted shares vesting	$ 3,331	$ 4,970
Period for recognition	2 years 3 months 5 days

Stock-Based Compensation And Incentive Performance Plans (Summary Of Stock Option Activity) (Details) $ / shares in Units, shares in Thousands	9 Months Ended
	Mar. 31, 2019 USD ($) $ / shares shares
Number of Options
Options outstanding and exercisable, beginning balance (shares) \| shares	122
Exercised (shares) \| shares	0
Options outstanding and exercisable, ending balance (shares) \| shares	122
Weighted Average Exercise Price
Options outstanding and exercisable, beginning balance (USD per share) \| $ / shares	$ 2.26
Exercised (USD per share) \| $ / shares	0.00
Options outstanding and exercisable, ending balance (USD per share) \| $ / shares	$ 2.26
Weighted Average Contractual Life	12 years 3 months 18 days
Aggregate Intrinsic Value \| $	$ 2,544,000
Unrecognized compensation expense \| $	$ 0

Stock-Based Compensation And Incentive Performance Plans (Long-Term Incentive Plan) (Details) $ / shares in Units, $ in Thousands		3 Months Ended			9 Months Ended
	Jan. 24, 2019 USD ($) $ / shares shares	Mar. 31, 2019 USD ($) $ / shares shares	Sep. 30, 2018 USD ($) shares	Mar. 31, 2018 USD ($)	Mar. 31, 2019 USD ($) plan $ / shares shares	Mar. 31, 2018 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of long-term incentive plans \| plan					4
Compensation cost recognized \| $		$ 3,943		$ 2,936	$ 5,989	$ 10,258
PSUs [Member] \| Executives [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued (in shares)		101,000			101,000
PSUs [Member] \| Executives [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period					1 year
PSUs [Member] \| Executives [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period					2 years
Time Based Award [Member] \| Select New Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued (in shares)		201,000			201,000
Vesting period					3 years
Long Term Incentive Plan 2019-2021 [Member] \| PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued (in shares)	912,000
Percent of targeted award	100.00%
Vesting period	3 years
Compound Annual Total Shareholder Return over Performance Period (in shares)	0
Annual total shareholder return percent	15.00%
Shares subject to holding period (in shares)	451,000
Holding period	1 year
Grant date fair value \| $	$ 5,132
Compensation cost recognized \| $		$ 432			$ 432
Long Term Incentive Plan 2019-2021 [Member] \| PSUs [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of shares granted	0.00%
Grant date fair value (USD per share) \| $ / shares	$ 5.99
Long Term Incentive Plan 2019-2021 [Member] \| PSUs [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of shares granted	300.00%
Grant date fair value (USD per share) \| $ / shares	$ 5.26
Long Term Incentive Plan 2019-2021 [Member] \| Time Based Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued (in shares)		156,000			156,000
Vesting period					3 years
Long Term Incentive Plan 2018-2020 [Member] \| PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued (in shares)		45,000			45,000
Grant date fair value (USD per share) \| $ / shares		$ 18.32			$ 18.32
Grant date fair value \| $		$ 819			$ 819
Long Term Incentive Plan 2016-2018 and 2017-2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Conversion of common stock (in shares)					1
Award requisite service period					3 years
Long Term Incentive Plan 2016-2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award requisite service period			3 years
Forfeited (shares)			223,000
Reversal of previously accrued amounts \| $			$ 6,482
Long Term Incentive Plan 2016-2018 [Member] \| Chief Executive Officer Succession Plan expense, net
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reversal of previously accrued amounts \| $			5,065
Long Term Incentive Plan 2017-2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reversal of previously accrued amounts \| $			$ 1,129		$ (1,867)

Stock-Based Compensation And Incentive Performance Plans (2019 Equity Inducement Award Program) (Details) - 2019 Equity Inducement Award Program [Member] - PSUs [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 29, 2019	Feb. 19, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued (in shares)	926,000	187,000	739,000
Percent of targeted award	300.00%
Vesting period	3 years
Holding period	1 year
Grant date fair value (USD per share)		$ 3.01	$ 1.79
Grant date fair value	$ 1,887	$ 563	$ 1,324
Compound Annual Total Shareholder Return over Performance Period (in shares)	0
Annual total shareholder return percent	15.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued (in shares)	0
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued (in shares)	926,000

Stock-Based Compensation And Incentive Performance Plans (CEO Inducement Grant) (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended		9 Months Ended
	Jan. 24, 2019	Nov. 06, 2018	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost recognized			$ 3,943	$ 2,936	$ 5,989	$ 10,258
PSUs [Member] \| Mr. Schiller [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)		1,050,000
Vesting period		3 years
Compound Annual Total Shareholder Return over Performance Period (in shares)		0
Award requisite service period		3 years
Holding period		1 year
Grant date fair value		$ 7,571
Grant date fair value (USD per share)		$ 7.21
Compensation cost recognized			621		1,008
PSUs [Member] \| Mr. Schiller [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compound Annual Total Shareholder Return over Performance Period (in shares)		0
Annual total shareholder return percent		15.00%
PSUs [Member] \| Mr. Schiller [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compound Annual Total Shareholder Return over Performance Period (in shares)		1,050,000
Time Based Award [Member] \| Mr. Schiller [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)		79,000
Vesting period		3 years
Long Term Incentive Plan 2019-2021 [Member] \| PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)	912,000
Vesting period	3 years
Compound Annual Total Shareholder Return over Performance Period (in shares)	0
Annual total shareholder return percent	15.00%
Holding period	1 year
Grant date fair value	$ 5,132
Compensation cost recognized			$ 432		$ 432
Long Term Incentive Plan 2019-2021 [Member] \| PSUs [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value (USD per share)	$ 5.99
Long Term Incentive Plan 2019-2021 [Member] \| PSUs [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value (USD per share)	$ 5.26
Long Term Incentive Plan 2019-2021 [Member] \| Time Based Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)			156,000		156,000
Vesting period					3 years

Investments (Details) - Chop't [Member] - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018	Oct. 27, 2015
Schedule of Equity Method Investments [Line Items]
Ownership percentage		13.40%	14.90%
Ownership percentage diluted basis	11.90%
Equity method investments	$ 14,622	$ 15,524

Financial Instruments Measured At Fair Value (Assets And Liabilities Measured At Fair Value On A Recurring Basis) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Assets:
Cash equivalents		$ 99
Rabbi trust investments	$ 34,452
Forward foreign currency contracts	40	365
Equity investment	661	692
Contingent consideration, current	1,735
Assets total	36,888	1,156
Liabilities:
Forward foreign currency contracts	702	27
Contingent consideration, non-current	0	1,909
Liabilities total	702	1,936
Quoted Prices In Active Markets (Level 1) [Member]
Assets:
Cash equivalents		99
Rabbi trust investments	34,452
Forward foreign currency contracts	0	0
Equity investment	661	692
Contingent consideration, current	0
Assets total	35,113	791
Liabilities:
Forward foreign currency contracts	0	0
Contingent consideration, non-current	0	0
Liabilities total	0	0
Significant Other Observable Inputs (Level 2) [Member]
Assets:
Cash equivalents		0
Rabbi trust investments	0
Forward foreign currency contracts	40	365
Equity investment	0	0
Contingent consideration, current	0
Assets total	40	365
Liabilities:
Forward foreign currency contracts	702	27
Contingent consideration, non-current	0	0
Liabilities total	702	27
Significant Unobservable Inputs (Level 3) [Member]
Assets:
Cash equivalents		0
Rabbi trust investments	0
Forward foreign currency contracts	0	0
Equity investment	0	0
Contingent consideration, current	1,735
Assets total	1,735	0
Liabilities:
Forward foreign currency contracts	0	0
Contingent consideration, non-current	0	1,909
Liabilities total	$ 0	$ 1,909

Financial Instruments Measured At Fair Value (Summary Of Level 3 Activity) (Details) $ in Thousands	9 Months Ended
	Mar. 31, 2019 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance as of June 30, 2018	$ 1,909
Contingent consideration adjustment	(147)
Translation adjustment	(27)
Balance as of March 31, 2019	$ 1,735

Financial Instruments Measured At Fair Value (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of foreign exchange hedges discontinued	$ 0	$ 0	$ 0	$ 0
Cash Flow Hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional amount	3,920,000		3,920,000
Fair value amounts of derivative contracts, net liability	(52,000)		(52,000)
Fair Value Hedging [Member] \| Not Designated as Hedging Instrument [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional amount	54,884,000		54,884,000		$ 20,986,000
Fair value amounts of derivative contracts, net liability	$ (610,000)		$ (610,000)
Fair value amounts of derivative contracts, net assets					$ 338,000

Commitments And Contingencies (Details) - complaint			1 Months Ended
Commitments And Contingencies (Details) - complaint	Apr. 26, 2017	Aug. 17, 2016	Dec. 29, 2016
Securities Complaints [Member]
Loss Contingencies [Line Items]
Number of complaints		3
Derivative Complaints [Member]
Loss Contingencies [Line Items]
Number of complaints			2
Barnes Complaint [Member]
Loss Contingencies [Line Items]
Number of complaints	2

Segment Information (Segment Data) (Details) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
Segment Information (Segment Data) (Details) $ in Thousands	Mar. 31, 2019 USD ($)	Mar. 31, 2018 USD ($)	Mar. 31, 2019 USD ($) segment	Mar. 31, 2018 USD ($)	Jun. 30, 2018 USD ($)
Segment Reporting Information [Line Items]
Number of operating segments \| segment			7
Net sales	$ 599,797	$ 632,720	$ 1,744,786	$ 1,838,171
Operating Income	23,865	29,254	(15,626)	89,460
Chief Executive Officer Succession Plan expense, net	455	0	30,156	0
Project Terra costs and other	9,408	4,831	29,613	13,750
Accounting review and remediation costs, net of insurance proceeds	0	3,313	4,334	6,406
Tradenames [Member]
Segment Reporting Information [Line Items]
Long-lived asset impairment	17,900				$ 5,632
United States [Member] \| Tradenames [Member]
Segment Reporting Information [Line Items]
Long-lived asset impairment	11,300
United Kingdom [Member] \| Tradenames [Member]
Segment Reporting Information [Line Items]
Long-lived asset impairment	2,787				532
Rest of World [Member] \| Tradenames [Member]
Segment Reporting Information [Line Items]
Long-lived asset impairment	3,813				$ 5,100
Operating Segments [Member]
Segment Reporting Information [Line Items]
Net sales	599,797	632,720	1,744,786	1,838,171
Operating Income	46,114	49,896	90,349	135,349
Operating Segments [Member] \| United States [Member]
Segment Reporting Information [Line Items]
Net sales	266,445	281,052	769,585	815,013
Operating Income	17,099	24,974	26,449	67,696
Operating Segments [Member] \| United Kingdom [Member]
Segment Reporting Information [Line Items]
Net sales	227,206	238,321	671,121	698,968
Operating Income	18,147	13,863	36,822	37,062
Operating Segments [Member] \| Rest of World [Member]
Segment Reporting Information [Line Items]
Net sales	106,146	113,347	304,080	324,190
Operating Income	10,868	11,059	27,078	30,591
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Operating Income	(22,249)	(20,642)	(105,975)	(45,889)
Chief Executive Officer Succession Plan expense, net	455		30,156
Project Terra costs and other	$ 7,562	4,175	21,045	7,429
Accounting review and remediation costs, net of insurance proceeds		$ 3,313	$ 4,334	11,406
Accounting review and remediation costs, net of insurance proceeds				6,406
Insurance proceeds from accounting review				$ (5,000)

Segment Information (Long-lived Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Segment Reporting Information [Line Items]
Long-lived assets	$ 380,800	$ 360,564
United States [Member]
Segment Reporting Information [Line Items]
Long-lived assets	115,243	99,650
United Kingdom [Member]
Segment Reporting Information [Line Items]
Long-lived assets	179,226	174,214
All Other [Member]
Segment Reporting Information [Line Items]
Long-lived assets	$ 86,331	$ 86,700

Segment Information (Net Sales) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 599,797	$ 632,720	$ 1,744,786	$ 1,838,171
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	279,609	296,635	807,899	860,987
United Kingdom [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	227,206	238,321	671,121	698,968
All Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 92,982	$ 97,764	$ 265,766	$ 278,216

Label	Element	Value
Accounting Standards Update 2014-09 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 163,000
Accounting Standards Update 2014-09 [Member] \| Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	163,000
Accounting Standards Update 2016-01 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
Accounting Standards Update 2016-01 [Member] \| Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	(348,000)
Accounting Standards Update 2016-01 [Member] \| AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 348,000